A Dark Vector Cognition product
10-K comparison

Waters (WAT) 10-K risk factor changes: FY2019 vs FY2018

The 2019-12-31 10-K against the 2018-12-31 one, compared heading by heading and sentence by sentence. One of these filings carries no fiscal year tag, so its year is the calendar year of the period end.

Item 1A0 rewritten177 added0 removed0 unchanged

All filing items599 rewritten2,246 added1,864 removed426 unchanged

Read the changesGo to Item 1A

Waters Form 10-K, every itemFY2019, filed 25 February 2020, against FY2018, filed 26 February 2019FY2019 on sec.govFY2018 on sec.govRead this filing

Summary

counted, not written

Sentences by item

22 items, with every count and a link to each item that changed

Underlined words on a shaded ground are new in FY2019; struck-through words were in FY2018. Sentences that are wholly new or wholly gone are labelled rather than marked.

Item 1A. Risk Factors

0 rewritten, 177 added, 0 removed, 0 unchanged

New section this year

Read the full itemFY2019 item · filed February 25, 2020

New in FY2019

Risk Factors

New in FY2019

The Company is subject to risks and uncertainties, including, but not limited to, the following:

New in FY2019

The Company’s international operations may be negatively affected by political events, wars or terrorism and regulatory changes, related to either a specific country or a larger region.

New in FY2019

These potential political, currency and economic disruptions, as well as foreign currency exchange rate fluctuations, could have a material adverse effect on the Company’s results of operations or financial condition.

New in FY2019

Approximately 71% and 72% of the Company’s net sales in 2019 and 2018, respectively, were outside of the United States and were primarily denominated in foreign currencies.

New in FY2019

In addition, the Company has considerable manufacturing operations in Ireland and the U.K., as well as significant subcontractors located in Singapore.

New in FY2019

As a result, a significant portion of the Company’s sales and operations are subject to certain risks, including adverse developments in the political, regulatory and economic environment, in particular, uncertainty regarding possible changes to foreign and domestic trade policy; the effect of the U.K.’s exit from the European Union as well as the financial difficulties and debt burden experienced by a number of European countries; the instability and potential impact of war or terrorism; the instability and possible dissolution of the Euro as a single currency; sudden movements in a country’s foreign exchange rates due to a change in a country’s sovereign risk profile or foreign exchange regulatory practices; tariffs and other trade barriers; the impact of public health epidemics, such as the coronavirus currently impacting China and elsewhere; difficulties in staffing and managing foreign operations; and associated adverse operational, contractual and tax consequences.

New in FY2019

Additionally, the U.S. dollar value of the Company’s net sales, cost of sales, operating expenses, interest, taxes and net income varies with foreign currency exchange rate fluctuations.

New in FY2019

Significant increases or decreases in the value of the U.S. dollar relative to certain foreign currencies, particularly the Euro, Japanese yen and British pound, could have a material adverse effect or benefit on the Company’s results of operations or financial condition.

New in FY2019

Global economic conditions may decrease demand for the Company’s products and harm the Company’s financial results.

New in FY2019

The Company is a global business that may be adversely affected by changes in global economic conditions.

New in FY2019

These changes in global economic conditions, both inside and outside the U.S., may affect the demand for the Company’s products and services.

New in FY2019

This may result in a decline in sales in the future, increased rate of order cancellations or delays, increased risk of excess or obsolete inventories, longer sales cycles and potential difficulty in collecting sales proceeds.

New in FY2019

There can be no assurance regarding demand for the Company’s products and services in the future.

New in FY2019

The Company’s financial results are subject to changes in customer demand, which may decrease for a number of reasons, many beyond the Company’s control.

New in FY2019

The demand for the Company’s products is dependent upon the size of the markets for its LC,

New in FY2019

LC-MS,

New in FY2019

thermal analysis, rheometry and calorimetry products; the timing and level of capital spending and expenditures of the Company’s customers; changes in governmental regulations, particularly affecting drug, food and drinking water testing; funding available to academic, governmental and research institutions; general economic conditions and the rate of economic growth in the Company’s major markets; and competitive considerations.

New in FY2019

The Company typically experiences an increase in sales in its fourth quarter as a result of purchasing habits for capital goods by customers that tend to exhaust their spending budgets by calendar year end.

New in FY2019

However, there can be no assurance that the Company will effectively forecast customer demand and appropriately allocated research and development expenditures to products with high growth and high margin prospects.

New in FY2019

Additionally, there can be no assurance that the Company’s results of operations or financial condition will not be adversely impacted by a change in any of the factors listed above or the continuation of uncertain global economic conditions.

New in FY2019

Additionally, the analytical instrument market may, from time to time, experience low sales growth.

New in FY2019

Approximately 57% and 56% of the Company’s net sales in 2019 and 2018, respectively, were to worldwide pharmaceutical and biotechnology companies, which may be periodically subject to unfavorable market conditions and consolidations.

New in FY2019

Unfavorable industry conditions could have a material adverse effect on the Company’s results of operations or financial condition.

New in FY2019

Disruption in worldwide financial markets could adversely impact the Company’s access to capital and financial condition.

New in FY2019

Financial markets in the U.S., Europe and Asia have experienced times of extreme disruption, including, among other things, sharp increases in the cost of new capital, credit rating downgrades and bailouts, severely diminished capital availability and severely reduced liquidity in money markets.

New in FY2019

Financial and banking institutions have also experienced disruptions, resulting in large asset write-downs, higher costs of capital, rating downgrades and reduced desire to lend money.

New in FY2019

There can be no assurance that there will not be future deterioration or prolonged disruption in financial markets or financial institutions.

New in FY2019

Any future deterioration or prolonged disruption in financial markets or financial institutions in which the Company participates may impair the Company’s ability to access its existing cash, utilize its existing syndicated bank credit facility funded by such financial institutions, and impair its ability to access sources of new capital.

New in FY2019

The cost to the Company of any new capital raised and interest expense would increase if this were to occur.

New in FY2019

Competitors may introduce more effective or less expensive products than the Company’s, which could result in decreased sales.

New in FY2019

The competitive landscape may transform as a result of potential changes in ownership, mergers and continued consolidations among the Company’s competitors, which could harm the Company’s business.

New in FY2019

The analytical instrument market and, in particular, the portion related to the Company’s HPLC, UPLC,

New in FY2019

LC-MS,

New in FY2019

thermal analysis, rheometry and calorimetry product lines, is highly competitive and subject to rapid changes in technology.

New in FY2019

The Company encounters competition from several international instrument suppliers and other companies in both domestic and foreign markets.

New in FY2019

Some competitors have instrument businesses that are generally more diversified than the Company’s business, but are typically less focused on the Company’s chosen markets.

New in FY2019

Over the years, some competitors have merged with other competitors for various reasons, including increasing product line offerings, improving market share and reducing costs.

New in FY2019

There can be no assurance that the Company’s competitors will not introduce more effective and less costly products than those of the Company or that the Company will be able to increase its sales and profitability from new product introductions.

New in FY2019

There can be no assurance that the Company’s sales and marketing forces will compete successfully against the Company’s competitors in the future.

An excerpt. Shown here: all 0 rewritten, 40 of 177 added and all 0 removed. The counts are complete. For every sentence, read Item 1A. Risk Factors in the FY2019 filing.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations

248 rewritten, 122 added, 130 removed, 160 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

[removed: Business] [added: Business] and Financial [removed: Overview][added: Overview]

Rewritten

The Company has two operating segments: [removed: WatersTM and TATM.][added: Waters]

Rewritten

[removed: Waters products and services primarily consist of high performance liquid chromatography (“HPLC”), ultra performance liquid chromatography (“UPLCTM”] [added: ”] and together with HPLC, referred to as “LC”), mass spectrometry (“MS”) and precision chemistry consumable products and related services.

Rewritten

The Company’s operating results are as follows for the years ended December 31, [removed: 2018, 2017] [added: 2019, 2018] and [removed: 2016] [added: 2017] (dollars in thousands, except per share data):

Rewritten

| | | [removed: Year] [added: Year] Ended December [removed: 31,] [added: 31,] | | | | | | | | | | | | [removed: _% change_] [added: % change] | | | | | | |

Rewritten

| | | [removed: 2018] [added: 2019] | | | | [removed: 2017] [added: 2018] | | | | [removed: 2016] [added: 2017] | | | | [removed: _2018] [added: 2019] vs. [removed: 2017_] [added: 2018] | | | | [removed: _2017] [added: 2018] vs. [removed: 2016_] [added: 2017] | | |

Rewritten

| Product sales | | $ | [removed: 1,604,993] [added: 1,567,189] | | | $ | [removed: 1,552,349] [added: 1,604,993] | | | $ | [removed: 1,460,296] [added: 1,552,349] | | | | [removed: _3_] [added: (2] | [removed: _%_] [added: %)] | | | [removed: _6_] [added: 3] | [removed: _%_] [added: %] |

Rewritten

| Service sales | | | [removed: 814,936] [added: 839,407] | | | | [removed: 756,729] [added: 814,936] | | | | [removed: 707,127] [added: 756,729] | | | | [removed: _8_] [added: 3] | [removed: _%_] [added: %] | | | [removed: _7_] [added: 8] | [removed: _%_] [added: %] |

Rewritten

| Total net sales | | | [removed: 2,419,929] [added: 2,406,596] | | | | [removed: 2,309,078] [added: 2,419,929] | | | | [removed: 2,167,423] [added: 2,309,078] | | | | [removed: _5_] [added: (1] | [removed: _%_] [added: %)] | | | [removed: _7_] [added: 5] | [removed: _%_] [added: %] |

Rewritten

| Cost of sales | | | [removed: 992,564] [added: 1,010,700] | | | | [removed: 947,067] [added: 992,564] | | | | [removed: 891,453] [added: 947,067] | | | | [removed: _5_] [added: 2] | [removed: _%_] [added: %] | | | [removed: _6_] [added: 5] | [removed: _%_] [added: %] |

Rewritten

| Selling and administrative expenses | | | [removed: 536,902] [added: 534,791] | | | | [removed: 544,363] [added: 536,902] | | | | [removed: 512,331] [added: 544,363] | | | | [removed: _(1_] [added: —] | [removed: _%)_] | | | [removed: _6_] [added: (1] | [removed: _%_] [added: %)] |

Rewritten

| Research and development expenses | | | [removed: 143,403] [added: 142,955] | | | | [removed: 132,593] [added: 143,403] | | | | [removed: 125,187] [added: 132,593] | | | | [removed: _8_] [added: —] | [removed: _%_] | | | [removed: _6_] [added: 8] | [removed: _%_] [added: %] |

Rewritten

| Purchased intangibles amortization | | | [removed: 7,712] [added: 9,693] | | | | [removed: 6,743] [added: 7,712] | | | | [removed: 9,889] [added: 6,743] | | | | [removed: _14_] [added: 26] | [removed: _%_] [added: %] | | | [removed: _(32_] [added: 14] | [removed: _%)_] [added: %] |

Rewritten

| Litigation (settlement) provision | | | [removed: (426] [added: —] | [removed: )] | | | [removed: 11,114] [added: (426] | [added: )] | | | [removed: 3,524] [added: 11,114] | | | | [removed: _(104_] [added: 100] | [removed: _%)_] [added: %] | | | [removed: _215_] [added: (104] | [removed: _%_] [added: %)] |

Rewritten

| Acquired in-process research and development | | | — | | | | [removed: 5,000] [added: —] | | | | [removed: —] [added: 5,000] | | | | [removed: _(100_] [added: —] | [removed: _%)_] | | | [removed: _—_] [added: (100] | [added: %)] |

Rewritten

| Operating income | | | [removed: 739,774] [added: 708,457] | | | | [removed: 662,198] [added: 739,774] | | | | [removed: 625,039] [added: 662,198] | | | | [removed: _12_] [added: (4] | [removed: _%_] [added: %)] | | | [removed: _6_] [added: 12] | [removed: _%_] [added: %] |

Rewritten

| [removed: _Operating] [added: Operating] income as a % of [removed: sales_] [added: sales] | | | [removed: _30.6_] [added: 29.4] | [removed: _%_] [added: %] | | | [removed: _28.7_] [added: 30.6] | [removed: _%_] [added: %] | | | [removed: _28.8_] [added: 28.7] | [removed: _%_] [added: %] | | | | | | | | |

Rewritten

| Other expense | | | [removed: (47,794] [added: (3,586] | ) | | | [removed: (340] [added: (47,794] | ) | | | [removed: (700] [added: (340] | ) | | | [removed: _*_] | [removed: _*_] | | | [removed: _51_] | [removed: _%_] |

Rewritten

| Interest expense, net | | | [removed: (9,834] [added: (26,632] | ) | | | [removed: (20,761] [added: (9,834] | ) | | | [removed: (24,225] [added: (20,761] | ) | | | [removed: _(53_] [added: 171] | [removed: _%)_] [added: %] | | | [removed: _(14_] [added: (53] | [removed: _%)_] [added: %)] |

Rewritten

| Income before income taxes | | | [removed: 682,146] [added: 678,239] | | | | [removed: 641,097] [added: 682,146] | | | | [removed: 600,114] [added: 641,097] | | | | [removed: _6_] [added: (1] | [removed: _%_] [added: %)] | | | [removed: _7_] [added: 6] | [removed: _%_] [added: %] |

Rewritten

| Provision for income taxes | | | [removed: 88,352] [added: 86,041] | | | | [removed: 620,786] [added: 88,352] | | | | [removed: 78,611] [added: 620,786] | | | | [removed: _(86_] [added: (3] | [removed: _%)_] [added: %)] | | | [removed: _690_] [added: (86] | [removed: _%_] [added: %)] |

Rewritten

| Net income | | $ | [removed: 593,794] [added: 592,198] | | | $ | [removed: 20,311] [added: 593,794] | | | $ | [removed: 521,503] [added: 20,311] | | | | [removed: _*_] [added: —] | [removed: _*_] | | | [removed: _(96_] | [removed: _%)_] |

Rewritten

| Net income per diluted common share | | $ | [removed: 7.65] [added: 8.69] | | | $ | [removed: 0.25] [added: 7.65] | | | $ | [removed: 6.41] [added: 0.25] | | | | [removed: _*_] [added: 14] | [removed: _*_] [added: %] | | | [removed: _(96_] | [removed: _%)_] |

Rewritten

[removed: |] [removed: |] Percentage not meaningful [removed: |]

Rewritten

The Company’s net sales [removed: increased 5%] [added: decreased approximately 1%] in [removed: 2018] [added: 2019] as compared to [removed: 2017,] [added: 2018,] and [removed: 7%] [added: increased 5%] in [removed: 2017] [added: 2018] as compared to [removed: 2016.][added: 2017.]

Rewritten

Foreign currency translation [added: decreased sales by 2% in 2019 and] increased sales [removed: growth] by 1% in [removed: both 2018 and 2017.][added: 2018.]

Rewritten

Instrument system sales [added: decreased 4% and] increased 2% [removed: and 6%] in [removed: 2018] [added: 2019] and [removed: 2017,] [added: 2018,] respectively.

Rewritten

Recurring revenues (combined sales of precision chemistry consumables and services) increased [removed: 8%] [added: 3%] and [removed: 7%] [added: 8%] in [removed: 2018] [added: 2019] and [removed: 2017,] [added: 2018,] respectively, as a result of a larger installed base of customers and higher billing demand for service sales.

Rewritten

[removed: Geographically, the] [added: The] Company’s sales growth in [removed: both] 2018 [removed: and 2017] was primarily driven by the 7% [removed: and 10%] sales growth in Asia, [removed: respectively,] with [removed: double-digit] [added: China’s] sales [removed: growth in China for both years.][added: growing 15%.]

Rewritten

Sales to pharmaceutical customers [added: were flat in 2019 and] grew 5% [removed: and 7%] in [removed: 2018 and 2017, respectively.][added: 2018.]

Rewritten

[removed: These increases were driven by] [added: Offsetting those declines was an increase in] the [removed: increasing] need for global access to prescription drugs and the testing of newer and [removed: more] complex biologic drugs.

Rewritten

Combined sales to industrial customers, which include [removed: materials] [added: material] characterization, food, environmental and fine chemical markets, [removed: grew] [added: declined] 2% [removed: and 4%] in [removed: 2018] [added: 2019] and [removed: 2017, respectively.][added: grew 2% in 2018.]

Rewritten

Combined sales to [removed: governmental and] academic [added: and governmental] customers increased [added: 2% in 2019 and] 8% in [removed: both 2018] [added: 2018, with the effect of foreign currency translation decreasing sales by 1% in 2019] and [removed: 2017.][added: increasing sales by 1% in 2018.]

Rewritten

Sales to [removed: governmental and] academic [added: and governmental] customers are highly dependent on when institutions receive funding to purchase our instrument systems and, as such, sales growth rates can vary significantly from period to period.

Rewritten

Operating income [removed: was $740 million in 2018, an increase of] [added: increased] 12% [added: in 2018] as compared to 2017.

Rewritten

The Company’s effective tax rates were [removed: 13.0%, 96.8%] [added: 12.7%, 13.0%] and [removed: 13.1%] [added: 96.8%] for [removed: 2018, 2017] [added: 2019, 2018] and [removed: 2016,] [added: 2017,] respectively.

Rewritten

Net income per diluted share was [removed: $7.65, $0.25] [added: $8.69, $7.65] and [removed: $6.41] [added: $0.25] in [removed: 2018, 2017] [added: 2019, 2018] and [removed: 2016,] [added: 2017,] respectively.

Rewritten

The Company generated [removed: $604] [added: $643] million, [removed: $698] [added: $604] million and [removed: $643] [added: $698] million of net cash flows from operations in [removed: 2018, 2017] [added: 2019, 2018] and [removed: 2016,] [added: 2017,] respectively.

Rewritten

The [removed: decrease] [added: increase] in operating cash flow in [removed: 2018] [added: 2019] was primarily a result of [added: payments made in 2018 that did not recur, including] $103 million of income tax payments made in the U.S. relating to the Company’s estimated 2017 transition tax liability and 2018 estimated tax payments, a $15 million litigation settlement payment and $11 million of contributions to certain defined benefit pension plans.

Rewritten

Over the next [removed: four] [added: three] years, the Company is required to make annual U.S. federal tax payments of approximately $38 million to tax authorities in connection with the Company’s estimated [added: remaining] transition tax liabilities of [removed: $433] [added: $404] million under the 2017 Tax Act.

New in FY2019

TM

New in FY2019

and TA

New in FY2019

TM

New in FY2019

Waters products and services primarily consist of high performance liquid chromatography (“HPLC”), ultra performance liquid chromatography (“UPLC

New in FY2019

TM

New in FY2019

In 2019, the decrease in instrument system sales was primarily driven by weaker demand for our products by our customers due to uncertainty caused by macroeconomic conditions and governmental policy changes.

New in FY2019

Foreign currency translation decreased instrument system sales by 1% in 2019 and increased instrument system sales by 1% in 2018.

New in FY2019

Recurring revenues were impacted by foreign currency, which decreased sales by 2% in 2019 and increased sales by 2% in 2018.

New in FY2019

Geographically, the decline in the Company’s sales in 2019 was a result of increased sales in the U.S., Canada, Japan and the rest of Asia being offset by a decrease in sales in other geographies on weaker demand for our products due to uncertainty caused by macroeconomic conditions, primarily from Brexit as well as Latin America, and governmental policy changes in China.

New in FY2019

In addition, the effect of foreign currency translation negatively impacted sales by 2% overall.

New in FY2019

Sales in Europe decreased 4% in 2019 and increased 4% in 2018.

New in FY2019

In 2019, Europe sales were impacted by weak demand in Western Europe caused by the political uncertainties of Brexit and the effect of foreign currency translation, which reduced sales by 4% in 2019 and increased sales by 3% in 2018.

New in FY2019

Sales in the Americas decreased 1% in 2019 and increased 3% in 2018.

New in FY2019

The Americas sales in 2019 were negatively impacted by macroeconomic conditions in Latin America, and the 2018 Americas sales growth can be attributed to the increase in sales after the lower customer demand stemming from the 2017 natural disasters in the U.S., Mexico and Puerto Rico.

New in FY2019

Sales to pharmaceutical customers in 2019 were negatively impacted by the lower customer demand in China for our instrument systems as a result of changes in governmental policy and lower sales in Latin America.

New in FY2019

Despite the sales declines in China and Latin America, the need for global access to prescription drugs and the testing of newer and complex biologic drugs increased in the rest of the world.

New in FY2019

The 2019 industrial customer sales were negatively impacted by a 6% decline in TA instrument system sales and a 1% decline from the effect of foreign currency translation.

New in FY2019

Operating income was $708 million in 2019, a decrease of 4% as compared to 2018.

New in FY2019

This decrease can be attributed to lower sales volume, the effect of foreign currency translation and $10 million of severance-related costs in connection with a reduction in workforce that occurred in early 2019, offset by lower variable incentive compensation costs.

New in FY2019

In 2018, the Company settled a pension plan obligation and incurred a $46 million expense which reduced the net income per diluted share by $0.39.

New in FY2019

In 2017, The Company incurred a $550 million income tax provision related to the 2017 Tax Cuts and Jobs Act (“2017 Tax Act”) which reduced the net income per diluted share by $6.82, and excluding the 2017 Tax Act income tax provision, the Company’s effective tax rate in 2017 would have been 11.0%.

New in FY2019

Included in the 2019 net cash flow from operations is $29 million of income tax payments made in the U.S. in relation to the 2017 transition tax liability.

New in FY2019

In 2019, $68 million of capital expenditures paid related to the expansion of the Company’s precision chemistry consumable operations in the U.S. The Company has incurred $85 million of costs for this facility through the end of 2019.

New in FY2019

two-year

New in FY2019

period.

New in FY2019

As of December 31, 2019, the Company has a total of $1.7 billion authorized for future repurchases.

New in FY2019

In September 2019, the Company issued fixed interest rate senior unsecured notes with an aggregate principal amount of $500 million, of which $200 million of the outstanding notes matures in seven years and the remaining $300 million matures in 10 years.

New in FY2019

The Company used the proceeds from the issuance of these senior unsecured notes to repay other outstanding debt and for general corporate purposes.

New in FY2019

During 2019 and 2018, the Company entered into $260 million and $300 million, respectively, of

New in FY2019

U.S.-to-Euro

New in FY2019

In January 2020, the Company entered into a definitive agreement to acquire Andrew Alliance, an innovator in specialty laboratory automation technology, including software and robotics for approximately $80 million.

New in FY2019

This acquisition is not expected to have a material effect on the Company sales and expenses in 2020.

New in FY2019

In 2019, sales in China were negatively impacted by economic uncertainty caused by certain regulatory changes in our food and pharmaceutical markets.

New in FY2019

The 4% increase in sales in Japan was driven by instrument systems, primarily to pharmaceutical and academic and governmental customers, as well as foreign currency translation, which increased Japan’s sales by 2% in 2019.

New in FY2019

Sales growth in Asia Other was due primarily to pharmaceutical and academic and governmental customer classes in 2019.

New in FY2019

Sales in the U.S. increased by 1% despite large pharmaceutical customers slowing capital spending on our instrument systems.

New in FY2019

Sales declines in the rest of the Americas and Europe were broad-based across all product and customer classes due to macroeconomic conditions and political instability, except in Europe where sales to academic and governmental customers grew 8%.

New in FY2019

Sales in Europe were also negatively impacted by the effect of foreign currency translation, which decreased sales 4% in 2019.

New in FY2019

In 2019, sales to pharmaceutical customers were negatively impacted by the effect of foreign currency translation, which decreased sales to pharmaceutical customers by 2%, as well as a slower release of capital budgets by our customers due to uncertain macroeconomic conditions due to Brexit and regulatory changes in our food and pharmaceutical markets in China.

New in FY2019

The decline in sales to industrial customers in 2019 was due to weaker demand for our

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

Recent acquisitions did not have an impact on sales growth.

Dropped from FY2018

During 2018, the demand for our LC-MS instrument systems was somewhat unfavorably impacted by the timing of new product introductions, as many of the Company’s new products were not launched until the second half of 2018 or early in 2019.

Dropped from FY2018

In 2017, the demand for instrument system sales was balanced across our LC-MS and TA instrument systems.

Dropped from FY2018

Europe’s sales grew 4% and 10% in 2018 and 2017, respectively, and benefited from the effect of foreign currency translation, which added 3% and 2% to sales growth, respectively.

Dropped from FY2018

The Company’s 2018 sales were impacted by lower sales growth in India and Europe, resulting from lower customer demand for our instrument systems.

Dropped from FY2018

Sales in the Americas grew 3% in 2018 and were flat in 2017.

Dropped from FY2018

The Americas’ sales growth in 2017 was negatively impacted by natural disasters in the U.S., Mexico and Puerto Rico, as well as weaker customer sentiment in the first half of 2017.

Dropped from FY2018

The growth in both 2018 and 2017 was driven by recent product introductions and rising global regulatory standards in both food and materials markets.

Dropped from FY2018

Operating income increased 6% in 2017 as compared to 2016.

Dropped from FY2018

This increase was primarily a result of the effect of higher sales volume achieved in 2017, which was somewhat offset by the impact of $13 million of severance costs primarily associated with the closure of a facility in Germany and costs associated with providing U.S. employees with an early retirement transition incentive; an $11 million litigation settlement provision and related costs and a $5 million charge relating to a milestone payment for the licensing of certain intellectual property relating to mass spectrometry technologies yet to be commercialized.

Dropped from FY2018

The change in operating income in 2017 as compared with 2016 was also impacted by $4 million of expense in 2017 related to the acceleration of certain stock awards as compared to $7 million of similar expense in 2016.

Dropped from FY2018

The Company’s effective tax and net income per diluted share were impacted by the following items:

Dropped from FY2018

| | • | | In December 2018, the Company settled a pension plan obligation by making lump-sum cash payments and purchasing annuity contracts for participants to permanently extinguish the pension plan’s |

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

| | obligations. As a result, the Company recorded a $46 million charge, which consisted of a $6 million cash contribution to the plan and a $40 million non-cash charge related to the reversal of unrecognized actuarial losses recorded in accumulated other comprehensive income in the stockholders’ equity. The $46 million pre-tax charge reduced net income per diluted share by $0.39. |

Dropped from FY2018

| | • | | The significant increase in the provision for income taxes for 2017 was a result of the $550 million estimate for the impact of the enactment of the legislation informally referred to as the Tax Cuts and Jobs Act (the “2017 Tax Act”). The 2017 Tax Act changed the U.S. tax system to a territorial system, including broadening measures requiring the taxation of the Company’s historical unremitted foreign earnings through a deemed repatriation. This provision reduced net income per diluted share by $6.82 in 2017, and the Company’s effective tax rate was 11.0% excluding this $550 million provision. As permitted by the U.S. Securities and Exchange Commission (“SEC”) Staff Accounting Bulletin No. 118, the Company completed its analysis and calculation of the 2017 Tax Act federal and state transition tax liability during 2018, which remained significantly unchanged. |

Dropped from FY2018

The increase in operating cash flow in 2017 was primarily a result of the increase in sales and operating income.

Dropped from FY2018

The Company has spent $11 million on this facility through the end of 2018.

Dropped from FY2018

During the past three years, the Company has acquired technology to expand its future sales.

Dropped from FY2018

In 2017, the Company made a $7 million payment for an investment in a developer of analytical system solutions used to make measurements, predict stability and accelerate product discovery in the routine analytic, process monitoring and quality control release processes for life science and biopharmaceutical markets.

Dropped from FY2018

In addition, the Company made a milestone payment of $5 million in 2017 to acquire and license intellectual property.

Dropped from FY2018

In September 2016, the Company acquired Rubotherm GmbH for approximately $6 million in cash.

Dropped from FY2018

During 2018, the Company had net proceeds from the maturity of short-term investments of $1.8 billion.

Dropped from FY2018

The Company has conducted a post-tax reform evaluation of its capital allocation strategy and the Company is currently planning to use its existing cash, cash equivalents and investments, cash flow from operations and its available debt capacity to repurchase up to $4 billion of the Company’s common stock over the next two years.

Dropped from FY2018

The Company is currently planning to increase its outstanding debt balances to approximately 2.5 times the

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

Company’s net debt-to-earnings before interest, taxes, depreciation and amortization ratio to fund a significant portion of these share repurchases.

Dropped from FY2018

This new program replaced the remaining amounts available under the April 2018 authorization of $3 billion.

Dropped from FY2018

In

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

In 2017, the sales growth in Asia was driven by double-digit increases in China’s sales across all product and customer classes.

Dropped from FY2018

The increase in Asia Other in 2017 was driven by strong sales in India across all product and customer classes.

Dropped from FY2018

Japan’s sales in 2017 were driven by recurring revenue sales to governmental and academic customers.

Dropped from FY2018

Europe’s sales in 2017 were balanced across all product lines and driven by sales to pharmaceutical, governmental and academic customers.

Dropped from FY2018

Sales growth in the U.S. in 2017 was driven by TA instrument system sales and recurring revenues.

Dropped from FY2018

In 2017, sales to the rest of the world were impacted by a decrease in demand from industrial customers resulting from recent natural disasters.

Dropped from FY2018

In 2017, the growth within our pharmaceutical market was driven by double-digit growth in China, India and Europe.

Dropped from FY2018

Sales growth to the industrial market in 2017 was highest in China and India, with modest growth in other regions offset by flat sales in the Americas.

Dropped from FY2018

The increase in sales to governmental and academic customers in 2017 was broad-based across all geographies, with double-digit growth in Europe and the Americas.

An excerpt. Shown here: 40 of 248 rewritten, 40 of 122 added and 40 of 130 removed. The counts are complete. For every sentence, read Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations in the FY2019 filing and the FY2018 filing.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk

29 rewritten, 1,640 added, 3 removed, 20 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

[removed: _Derivative Transactions_][added: Derivative Transactions]

Rewritten

[removed: The Company is exposed to currency price risk on foreign currency exchange rate fluctuations when it translates its non-U.S.] dollar foreign subsidiaries’ financial statements into U.S. dollars, and when any of the Company’s subsidiaries purchase or sell products or services in a currency other than its own currency.

Rewritten

[removed: In 2018,] [added: As of December 31, 2019,] the Company [added: has] entered into three-year interest rate cross-currency swap derivative agreements with a notional value of [removed: $300] [added: $560] million to hedge the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated net asset investments.

Rewritten

Under hedge accounting, the change in fair value of the derivative that relates to changes in the foreign currency spot rate are recorded in the currency translation adjustment in other comprehensive income and remain in accumulated comprehensive income in stockholders’ [added: (deficit)] equity until the sale or substantial liquidation of the foreign operation.

Rewritten

| | | [removed: December] [added: December] 31, [removed: 2018] [added: 2018] | | | | | | | | [removed: December 31, 2017] | | | | | | |

Rewritten

| | | [removed: Notional Value] [added: Notional Value] | | | | [removed: Fair Value] [added: Fair Value] | | | | [removed: Notional Value] [added: Notional Value] | | | | [removed: Fair Value] [added: Fair Value] | | |

Rewritten

| Other current assets | | $ | [removed: 112,212] [added: 119,576] | | | $ | [removed: 503] [added: 16] | | | $ | [removed: 110,759] [added: 112,212] | | | $ | [removed: 566] [added: 503] | |

Rewritten

| Other current liabilities | | $ | [removed: 40,175] [added: 29,495] | | | $ | [removed: 224] [added: 1,028] | | | $ | [removed: 37,104] [added: 40,175] | | | $ | [removed: 182] [added: 224] | |

Rewritten

| Other assets | | $ | [removed: 300,000] [added: 560,000] | | | $ | [removed: 1,093] [added: 4,485] | | | $ | [removed: —] [added: 300,000] | | | $ | [removed: —] [added: 1,093] | |

Rewritten

| Accumulated other comprehensive income | | | | | | $ | [removed: (1,093] [added: (4,485] | ) | | | | | | $ | [removed: —] [added: (1,093] | [added: )] |

Rewritten

| | | [removed: Financial Statement Classification] [added: Financial Statement Classification] | | | | | | | | | | | | | [added: | |]

Rewritten

| | [removed: | Year] [added: Year] Ended December [removed: 31,] [added: 31,] | | | | | | | | | | | | | [added: | | |]

Rewritten

| | [added: 2019] | [removed: 2018] | | | [added: 2018] | [removed: 2017] | | | [added: 2017] | [removed: 2016] | | | | | [added: | |]

Rewritten

| Foreign currency exchange contracts: | | | | | | | | | | | | | | | [added: | |]

Rewritten

| Realized (losses) gains on closed contracts | | [added: |] Cost of sales | | [added: |] $ | [removed: (6,684] [added: (3,552] | ) | | $ | [removed: 3,894] [added: (6,684] | [added: )] | | $ | [removed: (10,401] [added: 3,894] | [removed: )] |

Rewritten

| Unrealized (losses) gains on open contracts | | [added: |] Cost of sales | | | [removed: (105] | [added: (1,292 |] ) | | | [removed: 1,054] [added: (105] | [added: )] | | | [removed: (883] [added: 1,054] | [removed: )] |

Rewritten

| Cumulative net pre-tax (losses) gains | | [added: |] Cost of sales | | [added: |] $ | [removed: (6,789] [added: (4,844] | ) | | $ | [removed: 4,948] [added: (6,789] | [added: )] | | $ | [removed: (11,284] [added: 4,948] | [removed: )] |

Rewritten

| Interest rate cross-currency swap agreements: | | | | | | | | | | | | | | | [added: | |]

Rewritten

| Interest earned | | [added: |] Interest income | | [added: |] $ | [removed: 2,713] [added: 11,709] | | | $ | [removed: —] [added: 2,713] | | | $ | — | |

Rewritten

| Unrealized gains on open contracts | | [added: |] Stockholders’ [added: (deficit)] equity | | [added: |] $ | [removed: 1,093] [added: 4,485] | | | $ | [removed: —] [added: 1,093] | | | $ | — | |

Rewritten

[removed: Assuming a hypothetical adverse change of 10% in year-end] exchange rates (a strengthening of the U.S. dollar), the fair market value of the foreign currency exchange contracts outstanding as of December 31, [removed: 2018] [added: 2019] would decrease [removed: pre-tax earnings by approximately $15 million.]

Rewritten

[removed: Assuming a hypothetical adverse change of 10% in year-end] exchange rates (a strengthening of the U.S. dollar), the fair market value of the interest rate cross-currency swap agreements outstanding as of December 31, [removed: 2018] [added: 2019] would increase by approximately [removed: $30] [added: $56] million and would be recorded to foreign currency translation in other comprehensive income within stockholders’ [added: (deficit)] equity.

Rewritten

The related impact on interest income would not have a material effect on [removed: pre-tax earnings.]

Rewritten

As of December 31, [removed: 2018,] [added: 2019,] the carrying value of the Company’s cash and cash equivalents approximated fair value.

Rewritten

As of December 31, [removed: 2018,] [added: 2019,] the Company estimates that a hypothetical adverse change of 100 basis points across all maturities would not have a material effect on the fair market value of its portfolio.

Rewritten

As of December 31, [removed: 2018] [added: 2019] and [removed: 2017, $471] [added: 2018, $249] million out of [removed: $1,735] [added: $337] million and [removed: $3,326] [added: $471] million out of [removed: $3,394] [added: $1,735] million, respectively, of the Company’s total cash, cash equivalents and investments were held by foreign subsidiaries.

Rewritten

In addition, [removed: $251] [added: $176] million out of [removed: $1,735] [added: $337] million and [removed: $304] [added: $251] million out of [removed: $3,394] [added: $1,735] million of cash, cash equivalents and investments were held in currencies other than the U.S. dollar at December 31, [removed: 2018] [added: 2019] and [removed: 2017,] [added: 2018,] respectively.

Rewritten

As of December 31, [removed: 2018,] [added: 2019,] the Company [removed: has] [added: had] no holdings in auction rate securities or commercial paper issued by structured investment vehicles.

Rewritten

[removed: Assuming a hypothetical adverse change of 10% in year-end] exchange rates (a strengthening of the U.S. dollar), the fair market value of the Company’s cash, cash equivalents and investments held in currencies other than the U.S. dollar as of December 31, [removed: 2018] [added: 2019] would decrease by approximately [removed: $25] [added: $18] million, of which the majority would be recorded to foreign currency translation in other comprehensive income within stockholders’ [added: (deficit)] equity.

New in FY2019

The Company is exposed to currency price risk on foreign currency exchange rate fluctuations when it translates its

New in FY2019

non-U.S.

New in FY2019

The Company’s principal strategies in managing exposures to changes in foreign currency exchange rates are to (1) naturally hedge the foreign-currency-denominated liabilities on the Company’s balance sheet against

New in FY2019

corresponding assets of the same currency, such that any changes in liabilities due to fluctuations in foreign currency exchange rates are typically offset by corresponding changes in assets and (2) mitigate foreign exchange risk exposure of international operations by hedging the variability in the movement of foreign currency exchange rates on a portion of its Euro-denominated net asset investments.

New in FY2019

| | | December 31, 2019 | | | | | | | | December 31, 2018 | | | | | | |

New in FY2019

Assuming a hypothetical adverse change of 10% in

New in FY2019

year-end

New in FY2019

pre-tax

New in FY2019

earnings by approximately $15 million.

New in FY2019

Assuming a hypothetical adverse change of 10% in

New in FY2019

year-end

New in FY2019

pre-tax

New in FY2019

earnings.

New in FY2019

Assuming a hypothetical adverse change of 10% in

New in FY2019

year-end

New in FY2019

| Item | 8: Financial Statements and Supplementary Data |

New in FY2019

Management’s Report on Internal Control Over Financial Reporting

New in FY2019

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules

New in FY2019

13a-15(f)

New in FY2019

and

New in FY2019

15d-15(f)

New in FY2019

under the Exchange Act.

New in FY2019

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

New in FY2019

Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

New in FY2019

Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in

New in FY2019

Internal Control — Integrated Framework (2013)

New in FY2019

issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

New in FY2019

Based on our evaluation under the framework in

New in FY2019

Internal Control — Integrated Framework (2013)

New in FY2019

, our management, including our chief executive officer and chief financial officer, concluded that our internal control over financial reporting was effective as of December 31, 2019.

New in FY2019

The effectiveness of our internal control over financial reporting as of December 31, 2019 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.

New in FY2019

Report of Independent Registered Public Accounting Firm

New in FY2019

To the Board of Directors and Stockholders of Waters Corporation

New in FY2019

Opinions on the Financial Statements and Internal Control over Financial Reporting

New in FY2019

We have audited the accompanying consolidated balance sheets of Waters Corporation and its subsidiaries (the “Company”) as of December 31, 2019 and 2018, and the related consolidated statements of operations, of comprehensive income, of stockholders’ equity (deficit) and of cash flows for each of the three years in the period ended December 31, 2019, including the related notes (collectively referred to as the “consolidated financial statements”).

New in FY2019

We also have audited the Company’s internal control over financial reporting as of December 31, 2019, based on criteria established in

New in FY2019

Internal Control — Integrated Framework

New in FY2019

(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

New in FY2019

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2019 and 2018, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2019 in conformity with accounting principles generally accepted in the United States of America.

New in FY2019

Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2019, based on criteria established in

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

##### [Table of Contents](#toc)

An excerpt. Shown here: all 29 rewritten, 40 of 1,640 added and all 3 removed. The counts are complete. For every sentence, read Item 7A. Quantitative and Qualitative Disclosures About Market Risk in the FY2019 filing and the FY2018 filing.

Item 1. Business

99 rewritten, 181 added, 208 removed, 139 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

[removed: General][added: General]

Rewritten

[removed: The Company] has pioneered analytical workflow solutions involving liquid chromatography, mass spectrometry and thermal analysis innovations serving the life, materials and food sciences for more than 60 years.

Rewritten

[removed: The Company primarily designs, manufactures, sells and services high performance liquid chromatography (“HPLC”), ultra performance liquid chromatography (“UPLCTM”] [added: ”] and together with HPLC, referred to as “LC”) and mass spectrometry (“MS”) technology systems and support products, including chromatography columns, other consumable products and comprehensive post-warranty service plans.

Rewritten

These systems are complementary products that are frequently employed together [removed: (“LC-MS”) and sold as integrated instrument systems using common software platforms.]

Rewritten

In addition, the Company designs, manufactures, sells and services thermal analysis, rheometry and calorimetry instruments through its [removed: TATM product line.][added: TA]

Rewritten

[removed: LC-MS] instruments combine a liquid phase sample introduction and separation system with mass spectrometric compound identification and quantification.

Rewritten

[removed: Business Segments][added: Business Segments]

Rewritten

As a result of this evaluation, the Company determined that it has two operating segments: [removed: WatersTM] [added: Waters] and [removed: TATM.][added: TA.]

Rewritten

Information concerning revenues and long-lived assets attributable to each of the Company’s products, services and geographic areas is set forth in Note [removed: 17] [added: 18] in the Notes to the Consolidated Financial Statements, which is incorporated herein by reference.

Rewritten

[removed: Waters] [added: Waters] Products and [removed: Markets][added: Markets]

Rewritten

[removed: _High] [added: High] Performance and Ultra Performance Liquid [removed: Chromatography_][added: Chromatography]

Rewritten

[removed: The most significant end-use] markets for HPLC are those served by the pharmaceutical and life science industries.

Rewritten

In 2004, Waters introduced a novel technology that the Company describes as ultra performance liquid chromatography that utilizes a packing material with small, uniform diameter particles and a specialized instrument, the ACQUITY [removed: UPLCTM, to accommodate the increased pressure and narrower chromatographic bands that are generated by these small and tightly packed particles.][added: UPLC]

Rewritten

[removed: In 2018, the Company introduced the ACQUITYTM ARCTM Bio System, a versatile, iron-free, bio-inert,] quaternary liquid chromatograph specifically engineered to improve bioseparation analytical methods.

Rewritten

[removed: The Company also introduced the ACQUITYTM UPLCTM] PLUS [removed: series in 2018, consisting of the H-Class PLUS, H-Class PLUS Bio and I-Class PLUS] systems, which incorporate foundational enhancements into the legacy systems.

Rewritten

Waters manufactures LC instruments that are offered in configurations that allow for varying degrees of automation, from component configured systems for academic teaching and research applications to fully automated systems for regulated and high sample throughput testing, and that have a variety of detection technologies, from optical-based ultra-violet (“UV”) absorbance, refractive index and fluorescence detectors to a suite of [removed: MS-based detectors, optimized for certain analyses.]

Rewritten

The Company believes that it is one of a few suppliers in the world that [removed: processes] [added: manufactures] silica and polymeric resins, packs columns and distributes its own products.

Rewritten

The Company believes that its ACQUITY UPLC lines of columns are used primarily on its [added: ACQUITY UPLC instrument systems and, furthermore, that its ACQUITY UPLC instruments primarily use ACQUITY UPLC columns.]

Rewritten

[removed: In 2018, the Company introduced the BioResolveTM] RP mAb Polyphenyl columns, which improve the consistency and reliability of the overly complex separations of monoclonal antibodies and antibody-drug conjugates.

Rewritten

[removed: In 2018, the Company introduced the VICAMTM BPATestTM,] [added: ,] which provides a sensitive, precise determination of Bisphenol A in as little as ten minutes.

Rewritten

VICAM also introduced a user-friendly lateral flow zearalenone strip test, the [removed: Zearala-V AQUATM in 2018.]

Rewritten

[removed: _Mass] [added: Mass] Spectrometry and Liquid Chromatography-Mass [removed: Spectrometry_][added: Spectrometry]

Rewritten

A wide variety of instrumental designs fall within the overall category of MS instrumentation, including devices that incorporate quadrupole, ion trap, [removed: time-of-flight (“Tof”), magnetic sector and ion mobility technologies.]

Rewritten

Furthermore, these technologies are often used in tandem [removed: (MS-MS) to maximize the speed and/or efficacy of certain experiments.]

Rewritten

[removed: The Company’s smaller-sized] mass spectrometers, such as the single quadrupole detector (“SQD”) and the tandem quadrupole detector (“TQD”), are often referred to as LC “detectors” and are typically sold as part of an LC system or as an LC system upgrade.

Rewritten

[removed: Larger quadrupole systems, such as the XevoTM TQ and XevoTM TQ-S] instruments, are used primarily for experiments performed for late-stage drug development, including clinical trial testing.

Rewritten

[removed: In 2018, the Company introduced the DART QDaTM system with LiveIDTM,] [added: ,] a direct-from-sample analytical system that verifies sample authenticity or adulteration, specifically for food applications.

Rewritten

[removed: The Company also introduced the XevoTM TQ-GC] mass spectrometer in 2018, which allows laboratories to meet and exceed low [removed: part-per-billion limits of detection when]

Rewritten

[removed: quantifying pesticide residues and other contaminants in food using GC-MS/MS] methods set forth by worldwide regulatory agencies/authorities.

Rewritten

[removed: In addition, the Company introduced the RenataDXTM] screening system, a flow-injection tandem mass spectrometry system for rapid high-throughput analysis of extracted dried blood spots and other human biological matrices.

Rewritten

In response to this development and to further promote the high utilization of these hybrid instruments, the Company has organized its Waters operating segment to develop, manufacture, sell and service integrated [removed: LC-MS systems.]

Rewritten

Based upon reports from independent marketing research firms and publicly-disclosed sales figures from competitors, the Company believes that it is one of the world’s largest manufacturers and distributors of LC and [removed: LC-MS instrument systems, chromatography columns and other consumables and related services.]

Rewritten

[removed: The Company’s newest software technology, UNIFITM,] [added: ,] is a scientific information system that is the culmination of a multi-year effort to substantially bring all of Waters’ preexisting, distinct software systems under one operating system.

Rewritten

[removed: UNIFI joins Waters’ suite of informatics products – EmpowerTM Chromatography Data Software, MassLynxTM Mass Spectrometry Software and NuGenesisTM] Scientific Data Management System, each of which is used to support innovations within world-leading institutions.

Rewritten

In 2018, the Company announced new analysis capabilities across a variety of molecules by integrating UNIFI acquired data from the Company’s [removed: VionTM IMS QTofTM or Xevo GS XS mass spectrometers with Molecular Discovery’s Mass-MetaSite and WebMetabase processing software.]

Rewritten

[removed: _Waters Service_][added: Waters Service]

Rewritten

[removed: The customer] benefits from improved budget control, data-driven technology adoption and accelerated workflow at a site or on a global perspective.

Rewritten

The servicing and support of instruments, software and accessories is an important source of revenue and [removed: represents] [added: represented] over [removed: 30%] [added: 35%] of sales for [removed: Waters.][added: Waters in 2019.]

Rewritten

[removed: Support plans typically involve scheduled] instrument [removed: maintenance and an agreement to promptly repair a non-functioning instrument] in return for a fee described in a contract that is priced according to the configuration of the instrument.

Rewritten

[removed: TA] [added: TA] Products and [removed: Markets][added: Markets]

New in FY2019

Waters

New in FY2019

TM

New in FY2019

The Company primarily designs, manufactures, sells and services high performance liquid chromatography (“HPLC”), ultra performance liquid chromatography (“UPLC

New in FY2019

TM

New in FY2019

(“LC-MS”)

New in FY2019

and sold as integrated instrument systems using common software platforms.

New in FY2019

TM

New in FY2019

product line.

New in FY2019

LC-MS

New in FY2019

The most significant

New in FY2019

end-use

New in FY2019

Waters also has in vitro diagnostic (IVD) labelled products that are used as general-purpose instruments for clinical diagnostic applications, such as newborn screening and therapeutic drug management, in countries where these products are registered.

New in FY2019

TM

New in FY2019

, to accommodate the increased pressure and narrower chromatographic bands that are generated by these small and tightly packed particles.

New in FY2019

In 2018, the Company introduced the ACQUITY ARC

New in FY2019

TM

New in FY2019

Bio System, a versatile, iron-free,

New in FY2019

bio-inert,

New in FY2019

The Company also introduced the ACQUITY

New in FY2019

UPLC PLUS series in 2018, consisting of the

New in FY2019

H-Class

New in FY2019

PLUS,

New in FY2019

H-Class

New in FY2019

PLUS Bio and

New in FY2019

I-Class

New in FY2019

In 2019, the Company introduced the ACQUITY

New in FY2019

TM

New in FY2019

Advanced Polymer Chromatography

New in FY2019

TM

New in FY2019

System, which is the first fully solvent-compatible UPLC system to perform size exclusion, gradient polymer elution and solvent compatible reversed-phase liquid chromatographic separations on a single platform.

New in FY2019

The

New in FY2019

all-in-one

New in FY2019

system gives research scientists greater analytical versatility and speed when conducting research on next-generation polymers.

New in FY2019

MS-based

New in FY2019

detectors, optimized for certain analyses.

New in FY2019

In 2018, the Company introduced the BioResolve

New in FY2019

TM

New in FY2019

In 2019, the Company introduced the BioResolv SCX mAb Columns and VanGuard

New in FY2019

TM

New in FY2019

FIT Cartridge technologies.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

ACQUITY UPLC instrument systems and, furthermore, that its ACQUITY UPLC instruments primarily use ACQUITY UPLC columns.

Dropped from FY2018

In 2016, the Company continued to expand its column chemistry capabilities through the introduction of CORTECSTM C8, CORTECSTM Phenyl, CORTECSTM T3 and CORTECSTM Shield RP18.

Dropped from FY2018

Quadrupole time-of-flight (“Q-TofTM”) instruments, such as the Company’s SYNAPTTM G2-S, are often used to analyze the role of proteins in disease processes, an application sometimes referred to as “proteomics”.

Dropped from FY2018

In 2016, the Company introduced the XevoTM TQ-XS mass spectrometry system enabled by the newly designed StepWaveTM SX ion guide, which features a unique combination of ion optics, detection and ionization technologies resulting in levels of sensitivity not previously seen.

Dropped from FY2018

The Company also introduced SONAR in 2016, which is a new data acquisition technology for use with the Xevo G2-XS that allows for the quantification and identification of lipids, metabolites and proteins in complex samples in a more efficient manner.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

In 2016, the Company announced two reference libraries available within UNIFI, the Metabolic Profiling CCS Library and the _Rapi_Fluor-MSTM Glycan GU Scientific Library.

Dropped from FY2018

The Company also introduced Symphony Data Pipeline software in 2016, which is a client-server application that automates the movement and transformation of large amounts of LC-MS data to speed up analytical workflows and liberate scientists from mundane yet necessary tasks associated with managing data files.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

In 2016, TA introduced a new line of differential scanning calorimeters and thermogravimetric analyzers.

Dropped from FY2018

These new Discovery DSC systems feature enhanced sensing technologies resulting in unprecedented performance in baseline flatness, sensitivity, resolution and reproducibility.

Dropped from FY2018

In addition, TA introduced the ACS-2 Air Chiller System, ElectroForce 3310 test instrument and DuraPulseTM Stent Graft test instrument in 2016.

Dropped from FY2018

In September 2016, the Company acquired all of the outstanding stock of Rubotherm GmbH (“Rubotherm”), a manufacturer of gravimetric analysis systems, for approximately $6 million in cash, $5 million of which was paid at closing and an additional $1 million paid after closing to settle certain liabilities.

Dropped from FY2018

Rubotherm develops and manufactures analytical test instruments for thermogravimetric and sorption measurements that are used in both industrial and academic research laboratories in disciplines that include chemistry, material science and engineering.

Dropped from FY2018

The Rubotherm acquisition has helped support and further expand product offerings within TA’s thermal analysis business.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

Regulation and the European In-Vitro Diagnostic Directive).

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

However, the Company does not have knowledge that any of its conflict minerals originated from the Democratic Republic of the Congo or adjoining countries.

Dropped from FY2018

The results of this and future evaluations may impose additional costs and may introduce new risks related to the Company’s ability to verify the origin of any conflict minerals contained in its products.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

each of its three primary technologies.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

| | changes in timing and demand for the Company’s products among the Company’s customers and various market sectors, particularly if they should reduce capital expenditures or are unable to obtain funding, as in the cases of governmental, academic and research institutions; the effect of mergers and acquisitions on customer demand for the Company’s products; and the Company’s ability to sustain and enhance service. |

Dropped from FY2018

The Company is subject to risks and uncertainties, including, but not limited to, the following:

Dropped from FY2018

_The Company’s international operations may be negatively affected by political events, wars or terrorism and regulatory changes, related to either a specific country or a larger region.

Dropped from FY2018

These potential political, currency and economic disruptions, as well as foreign currency exchange rate fluctuations, could have a material adverse effect on the Company’s results of operations or financial condition._

Dropped from FY2018

Approximately 72% and 71% of the Company’s net sales in 2018 and 2017, respectively, were outside of the United States and were primarily denominated in foreign currencies.

Dropped from FY2018

In addition, the Company has considerable manufacturing operations in Ireland and the United Kingdom, as well as significant subcontractors located in Singapore.

Dropped from FY2018

As a result, a significant portion of the Company’s sales and operations are subject to certain risks, including adverse developments in the political, regulatory and economic environment, in particular, uncertainty regarding possible changes to foreign and domestic trade policy; the effect of the U.K. voting to exit the European Union as well as the financial difficulties and debt burden experienced by a number of European countries; the instability and potential impact of war or terrorism; the instability and possible dissolution of the Euro as a single currency; sudden movements in a country’s foreign exchange rates due to a change in a country’s sovereign risk profile or foreign exchange regulatory practices; tariffs and other trade barriers; difficulties in staffing and managing foreign operations; and associated adverse operational, contractual and tax consequences.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

Additionally, the U.S. dollar value of the Company’s net sales, cost of sales, operating expenses, interest, taxes and net income varies with foreign currency exchange rate fluctuations.

Dropped from FY2018

Significant increases or decreases in the value of the U.S. dollar relative to certain foreign currencies, particularly the Euro, Japanese yen and British pound, could have a material adverse effect or benefit on the Company’s results of operations or financial condition.

Dropped from FY2018

_Global economic conditions may decrease demand for the Company’s products and harm the Company’s financial results._

Dropped from FY2018

The Company is a global business that may be adversely affected by changes in global economic conditions.

Dropped from FY2018

These changes in global economic conditions, both inside and outside the U.S., may affect the demand for the Company’s products and services.

An excerpt. Shown here: 40 of 99 rewritten, 40 of 181 added and 40 of 208 removed. The counts are complete. For every sentence, read Item 1. Business in the FY2019 filing and the FY2018 filing.

Item 3. Legal Proceedings

0 rewritten, 1 added, 0 removed, 2 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

New in FY2019

Legal Proceedings

Cover and table of contents

62 rewritten, 27 added, 11 removed, 6 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

[removed: UNITED] [added: UNITED] STATES SECURITIES AND EXCHANGE [removed: COMMISSION][added: COMMISSION]

Rewritten

[removed: Washington,] [added: Washington,] D.C. [removed: 20549][added: 20549]

Rewritten

[removed: Form 10-K][added: Form]

Rewritten

| ☑ | [removed: ANNUAL] [added: ANNUAL] REPORT PURSUANT TO SECTION 13 OR [removed: 15(d)] [added: 15(d)] |

Rewritten

| | [removed: OF] [added: OF] THE SECURITIES EXCHANGE ACT OF [removed: 1934] [added: 1934] |

Rewritten

[removed: For] [added: For] the fiscal year ended December 31, [removed: 2018][added: 2019]

Rewritten

| ☐ | [removed: TRANSITION] [added: TRANSITION] REPORT PURSUANT TO SECTION 13 OR [removed: 15(d)] [added: 15(d)] |

Rewritten

| | [removed: OF] [added: OF] THE SECURITIES EXCHANGE ACT OF [removed: 1934] [added: 1934] |

Rewritten

[removed: Commission] [added: Commission] File Number: [removed: 01-14010]

Rewritten

[removed: Waters Corporation][added: Waters Corporation]

Rewritten

[removed: _(Exact] [added: (Exact] name of registrant as specified in its [removed: charter)_][added: charter)]

Rewritten

| [removed: Delaware] [added: Delaware] | | [removed: 13-3668640] [added: 13-3668640] |

Rewritten

| [removed: _(State] [added: (State] or other jurisdiction [removed: of_ _incorporation] [added: of incorporation] or [removed: organization)_] [added: organization)] | | [removed: _(I.R.S. Employer_ _Identification No.)_] [added: (I.R.S. Employer Identification No.)] |

Rewritten

[removed: 34] [added: 34] Maple [removed: Street][added: Street]

Rewritten

[removed: Milford,] [added: Milford,] Massachusetts [removed: 01757][added: 01757]

Rewritten

[removed: _(Address,] [added: (Address,] including zip code, of principal executive [removed: offices)_][added: offices)]

Rewritten

[removed: (508) 478-2000][added: 478-2000]

Rewritten

[removed: _(Registrant’s] [added: (Registrant’s] telephone number, including area [removed: code)_][added: code)]

Rewritten

| Securities registered pursuant to Section 12(b) of the Act: | | [removed: Common Stock, par value $0.01 per share] |

Rewritten

Yes [removed: ☑ No ☐]

Rewritten

Yes [removed: ☐ No ☑]

Rewritten

Yes [removed: ☑ No ☐]

Rewritten

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation [removed: S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).]

Rewritten

Yes [removed: ☑ No ☐]

Rewritten

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a [removed: non-accelerated filer, a smaller reporting company, or emerging growth company.]

Rewritten

See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule [removed: 12b-2 of the Exchange Act.]

Rewritten

| Large accelerated filer ☑ | | Accelerated filer ☐ | | Non-accelerated filer ☐ | [removed: |] Smaller reporting company ☐ |

Rewritten

| | | | | | [removed: |] Emerging growth company ☐ |

Rewritten

Indicate by check mark whether the registrant is a shell company (as defined in Rule [removed: 12b-2 of the Act).]

Rewritten

Yes [removed: ☐ No ☑]

Rewritten

State the aggregate market value of the registrant’s common stock held by [removed: non-affiliates of the registrant as of June 30, 2018: $14,912,684,699.]

Rewritten

Indicate the number of shares outstanding of the registrant’s common stock as of February [removed: 22, 2019: 71,512,391][added: 21, 2020: 62,158,045]

Rewritten

[removed: DOCUMENTS] [added: DOCUMENTS] INCORPORATED BY [removed: REFERENCE][added: REFERENCE]

Rewritten

Portions of the registrant’s definitive proxy statement that will be filed for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders are incorporated by reference in Part III.

Rewritten

[removed: WATERS] [added: WATERS] CORPORATION AND [removed: SUBSIDIARIES][added: SUBSIDIARIES]

Rewritten

[removed: ANNUAL] [added: ANNUAL] REPORT ON FORM [removed: 10-K]

Rewritten

[removed: INDEX][added: INDEX]

Rewritten

| [removed: Item No.] [added: Item No.] | | | | | | [removed: Page] [added: Page] | | |

Rewritten

| | | | | [removed: PART I] [added: PART I] | | | | |

Rewritten

| | 1A. | | | [Risk [removed: Factors](#toc612944_2)] [added: Factors](#toc862312_2)] | | | [removed: 11] [added: 12] | |

New in FY2019

10-K

New in FY2019

or

New in FY2019

01-14010

New in FY2019

(508)

New in FY2019

| Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |

New in FY2019

| Common Stock, par value $0.01 per share | | WAT | | New York Stock Exchange, Inc. |

New in FY2019

No

New in FY2019

No

New in FY2019

No

New in FY2019

S-T

New in FY2019

(§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

New in FY2019

No

New in FY2019

non-accelerated

New in FY2019

filer, a smaller reporting company, or emerging growth company.

New in FY2019

12b-2

New in FY2019

of the Exchange Act.

New in FY2019

12b-2

New in FY2019

of the Act).

New in FY2019

No

New in FY2019

non-affiliates

New in FY2019

of the registrant as of June

New in FY2019

, 2019: $14,554,561,947.

New in FY2019

10-K

New in FY2019

| | 1. | | | [Business](#toc862312_1) | | | 1 | |

New in FY2019

| | 2. | | | [Properties](#toc862312_4) | | | 19 | |

New in FY2019

| | | | | [Information About Out Executive Officers](#toc862312_7) | | | 20 | |

New in FY2019

| | | | | [Signatures](#toc862312_23) | | | 104 | |

Dropped from FY2018

10-K 1 d612944d10k.htm 10-K

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

or

Dropped from FY2018

| Name of each exchange on which registered: | | New York Stock Exchange, Inc. |

Dropped from FY2018

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (§229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

| | 1. | | | [Business](#toc612944_1) | | | 1 | |

Dropped from FY2018

| | 2. | | | [Properties](#toc612944_4) | | | 20 | |

Dropped from FY2018

| | | | | [Executive Officers of the Registrant](#toc612944_7) | | | 21 | |

Dropped from FY2018

| | | | | [Signatures](#toc612944_23) | | | 106 | |

Dropped from FY2018

##### [Table of Contents](#toc)

An excerpt. Shown here: 40 of 62 rewritten, all 27 added and all 11 removed. The counts are complete. For every sentence, read Cover and table of contents in the FY2019 filing and the FY2018 filing.

Item 2. Properties

27 rewritten, 2 added, 1 removed, 16 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

Waters Corporation operates [removed: 22] [added: 23] United States facilities and [removed: 72] [added: 67] international facilities, including field offices.

Rewritten

[removed: _Primary] [added: Primary] Facility [removed: Locations_][added: Locations]

Rewritten

| [removed: Location] [added: Location] | | [removed: Function (1)] [added: Function (1)] | | [removed: Owned/Leased] | [added: | Owned/Leased | | |]

Rewritten

| Golden, CO | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]

Rewritten

| New Castle, DE | | [added: |] M, R, S, D, A | | [added: | |] Owned | [added: |]

Rewritten

| Franklin, MA | | [added: |] D | | [added: | |] Leased | [added: |]

Rewritten

| Milford, MA | | [added: |] M, R, S, A | | [added: | |] Owned | [added: |]

Rewritten

| Taunton, MA | | [added: |] M, R | | [added: | |] Owned | [added: |]

Rewritten

| Wakefield, MA | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]

Rewritten

| Eden Prairie, MN | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]

Rewritten

| Nixa, MO | | [added: |] M, S, D, A | | [added: | |] Leased | [added: |]

Rewritten

| Sharpsburg, PA | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]

Rewritten

| Lindon, UT | | [added: |] M, R, S, D, A | | [added: | |] Leased | [added: |]

Rewritten

| Newcastle, England | | [added: |] R, S, D, A | | [added: | |] Leased | [added: |]

Rewritten

| Solihull, England | | [added: |] M,A | | [added: | |] Owned | [added: |]

Rewritten

| Wilmslow, England | | [added: |] M, R, S, D, A | | [added: | |] Owned | [added: |]

Rewritten

| St. Quentin, France | | [added: |] S, A | | [added: | |] Leased | [added: |]

Rewritten

| Bochum, Germany | | [added: |] R, S, A | | [added: | |] Leased | [added: |]

Rewritten

| Huellhorst, Germany | | [added: |] M, R, S, D, A | | [added: | |] Owned | [added: |]

Rewritten

| Budapest, Hungary | | [added: |] R | | [added: | |] Leased | [added: |]

Rewritten

| Wexford, Ireland | | [added: |] M, R, D, A | | [added: | |] Owned | [added: |]

Rewritten

| Etten-Leur, Netherlands | | [added: |] S, D, A | | [added: | |] Owned | [added: |]

Rewritten

| Brasov, Romania | | [added: |] R, A | | [added: | |] Leased | [added: |]

Rewritten

| Singapore | | [added: |] R, S, D, A | | [added: | |] Leased | [added: |]

Rewritten

The Company operates and maintains 11 field offices in the United States and [removed: 61] [added: 56] field offices abroad in addition to sales offices in the primary facilities listed above.

Rewritten

[removed: _Field] [added: Field] Office Locations [removed: (2)_][added: (2)]

Rewritten

| [removed: United States] [added: United States] | | [removed: International] [added: International] | | | | |

New in FY2019

Properties

New in FY2019

| Cambridge, MA | | | R, S | | | | Leased | |

Dropped from FY2018

##### [Table of Contents](#toc)

Item 4. Mine Safety Disclosures

11 rewritten, 8 added, 14 removed, 24 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

O’Connell, [removed: 52,] [added: 53,] has served as a Director of the Company since September 2015, when he assumed the position of President and Chief Executive Officer of the Company.

Rewritten

[removed: Beaudouin, 64,] [added: Keeley Aleman, 43,] was appointed Senior Vice President, General Counsel and Secretary in [removed: February 2016 and was Vice President, General Counsel and Secretary] [added: October] of [removed: the Company since April 2003.][added: 2019.]

Rewritten

Buck, [removed: 55,] [added: 56,] was appointed Senior Vice President and Chief Financial Officer in January 2017.

Rewritten

Carson, [removed: 45,] [added: 46,] was appointed Senior Vice President, Corporate Development in February 2018.

Rewritten

Harrington, [removed: 58,] [added: 59,] was appointed Senior Vice President, Global Markets in February 2016.

Rewritten

Dr. Harrington joined Waters Corporation in 1987 and has held several senior positions with Waters Corporation, [added: including Vice President, Europe and Asia Pacific Operations, Senior Director of US Sales Operations, Director of US Chemistry Sales and General Manager of Phase Separations.]

Rewritten

[removed: Kelly, 56,] [added: Pratt, 50,] was appointed Senior Vice President and President, TA Instruments in [removed: February 2016.][added: August 2019.]

Rewritten

Francis Kim, [removed: 52,] [added: 53,] was appointed Senior Vice President, Global Operations in February 2018.

Rewritten

King, [removed: 62,] [added: 63,] was appointed Senior Vice President, Global Products in July 2017.

Rewritten

Rae, [removed: 61,] [added: 62,] was appointed Senior Vice President, Global Human Resources in February 2016 and was Vice President of Human Resources since October 2005 and Vice President of Worldwide Compensation and Benefits since January 2002.

Rewritten

[removed: PART II][added: PART II]

New in FY2019

Mine Safety Disclosures

New in FY2019

INFORMATION ABOUT OUR EXECUTIVE OFFICERS

New in FY2019

Ms. Aleman joined Waters Corporation in 2006 as the Assistant General Counsel and held various legal roles focusing on business transactions, commercial strategies, international development, compliance, corporate governance and organizational matters.

New in FY2019

Prior to joining Waters Corporation she held corporate associate positions at Goodwin Procter, LLP, and Testa, Hurwitz & Thibeault, LLP.

New in FY2019

Jonathan M.

New in FY2019

Prior to joining Waters Corporation, Mr. Pratt was President of Beckman Coulter Life Sciences.

New in FY2019

Additionally, he held senior positions at Pall Corporation, where he was President of its Food & Beverage, Laboratory and ForteBio businesses.

New in FY2019

On February 17, 2020, Mr. Kim notified the Company that he will be resigning his position on March 16, 2020.

Dropped from FY2018

EXECUTIVE OFFICERS OF THE REGISTRANT

Dropped from FY2018

Mark T.

Dropped from FY2018

Prior to joining Waters Corporation, he served as Senior Vice President, General Counsel and Secretary of PAREXEL International Corporation, a bio/pharmaceutical services company, from January 2000 to April 2003.

Dropped from FY2018

Previously, from May 1985 to January 2000, Mr. Beaudouin served in several senior legal management positions, including Vice President, General Counsel and Secretary of BC International, Inc., a development stage biotechnology company, First Senior Vice President, General Counsel and Secretary of J.

Dropped from FY2018

Baker, Inc., a diversified retail company, and General Counsel and Secretary of GenRad, Inc., a high technology test equipment manufacturer.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

including Vice President, Europe and Asia Pacific Operations, Senior Director of US Sales Operations, Director of US Chemistry Sales and General Manager of Phase Separations.

Dropped from FY2018

Terrance P.

Dropped from FY2018

Mr. Kelly has served as President, TA instruments since February 2005.

Dropped from FY2018

Mr. Kelly started his career in finance and accounting at ICI in 1985.

Dropped from FY2018

He joined DuPont in 1988.

Dropped from FY2018

He held various sales and marketing positions with DuPont, and later TA Instruments.

Dropped from FY2018

Mr. Kelly joined Waters Corporation in 1996, when TA Instruments was acquired.

Dropped from FY2018

##### [Table of Contents](#toc)

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

15 rewritten, 8 added, 11 removed, 7 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

As of February 21, [removed: 2019,] [added: 2020,] the Company had [removed: 86] [added: 80] common stockholders of record.

Rewritten

The Company has not made any sales of unregistered equity securities in the years ended December 31, [removed: 2018, 2017] [added: 2019, 2018] or [removed: 2016.][added: 2017.]

Rewritten

[removed: Securities] [added: Securities] Authorized for Issuance under Equity Compensation [removed: Plans][added: Plans]

Rewritten

[removed: Stock] [added: Stock] Price Performance [removed: Graph][added: Graph]

Rewritten

[removed: _The] [added: The] following performance graph and related information shall not be deemed to be “soliciting material” or to be “filed” with the SEC, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference into such [removed: filing._][added: filing.]

Rewritten

The following graph compares the cumulative total return on $100 invested as of December 31, [removed: 2013] [added: 2014] (the last day of public trading of the Company’s common stock in fiscal year [removed: 2013)] [added: 2014)] through December 31, [removed: 2018] [added: 2019] (the last day of public trading of the common stock in fiscal year [removed: 2018)] [added: 2019)] in the Company’s common stock, the NYSE Market Index, the SIC Code 3826 Index and the S&P 500 Index.

Rewritten

[removed: COMPARISON] [added: COMPARISON] OF CUMULATIVE TOTAL RETURN SINCE DECEMBER 31, [removed: 2013][added: 2014]

Rewritten

[removed: AMONG] [added: AMONG] WATERS CORPORATION, NYSE MARKET INDEX, SIC CODE 3826 INDEX – LABORATORY ANALYTICAL INSTRUMENTS AND S&P 500 [removed: INDEX][added: INDEX]

Rewritten

[removed: ![LOGO](https://www.sec.gov/Archives/edgar/data/1000697/000119312519051872/g612944g16l14.jpg)][added: ![](https://www.sec.gov/Archives/edgar/data/1000697/000119312520048303/g862312g16l14.jpg)]

Rewritten

| | | [removed: 2013] [added: 2014] | | | | [removed: 2014] [added: 2015] | | | | [removed: 2015] [added: 2016] | | | | [removed: 2016] [added: 2017] | | | | [removed: 2017] [added: 2018] | | | | [removed: 2018] [added: 2019] | | | [added: |]

Rewritten

[removed: Purchases] [added: Purchases] of Equity Securities by the [removed: Issuer][added: Issuer]

Rewritten

The following table provides information about purchases by the Company during the three months ended December 31, [removed: 2018] [added: 2019] of equity securities registered by the Company under the Exchange Act (in thousands, except per share data):

Rewritten

| [removed: Period] [added: Period] | | [removed: Total Number] [added: Total Number] of Shares Purchased [removed: (1)] [added: (1)] | | | | [removed: Average] [added: Average] Price Paid per [removed: Share] [added: Share] | | | | [removed: Total] [added: Total] Number of Shares Purchased as Part of Publicly Announced Programs [removed: (2)] [added: (2)] | | | | [removed: Maximum] [added: Maximum] Dollar Value of Shares that May Yet Be Purchased Under the Programs [removed: (2)] [added: (2)] | | |

Rewritten

| (1) | The [removed: Company repurchased 6 thousand shares of common stock at a cost of less than $1 million] [added: Company’s repurchase activity] related to the vesting of restricted stock units during the three months ended December 31, [removed: 2018.] [added: 2019 was insignificant.] |

Rewritten

| (2) | In [removed: April 2018, the Company’s Board of Directors authorized the repurchase of up to $3.5 billion of its outstanding common stock in open market or private transactions over a three-year period. In] January 2019, the Company’s Board of Directors authorized the Company to repurchase up to $4 billion of its outstanding common stock in open market or private transactions over a two-year period. This new program replaced the remaining amounts available under the [removed: April 2018] [added: pre-existing] authorization. |

New in FY2019

| WATERS CORPORATION | | $ | 100.00 | | | $ | 119.39 | | | $ | 119.22 | | | $ | 171.39 | | | $ | 167.36 | | | $ | 207.28 | | |

New in FY2019

| NYSE MARKET INDEX | | $ | 100.00 | | | $ | 95.91 | | | $ | 107.36 | | | $ | 127.46 | | | $ | 116.06 | | | $ | 145.66 | | |

New in FY2019

| SIC CODE INDEX | | $ | 100.00 | | | $ | 111.14 | | | $ | 102.42 | | | $ | 156.71 | | | $ | 165.13 | | | $ | 205.80 | | |

New in FY2019

| S&P 500 INDEX | | $ | 100.00 | | | $ | 101.38 | | | $ | 113.51 | | | $ | 138.29 | | | $ | 132.23 | | | $ | 173.86 | | |

New in FY2019

| September 29, 2019 to October 26, 2019 | | | 646 | | | $ | 217.06 | | | | 646 | | | $ | 2,112,901 | |

New in FY2019

| October 27, 2019 to November 23, 2019 | | | 797 | | | $ | 214.93 | | | | 797 | | | $ | 1,941,602 | |

New in FY2019

| November 24, 2019 to December 31, 2019 | | | 1,092 | | | $ | 228.96 | | | | 1,092 | | | $ | 1,691,643 | |

New in FY2019

| Total | | | 2,535 | | | $ | 221.52 | | | | 2,535 | | | $ | 1,691,643 | |

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

| WATERS CORPORATION | | $ | 100.00 | | | $ | 112.72 | | | $ | 134.58 | | | $ | 134.39 | | | $ | 193.19 | | | $ | 188.65 | |

Dropped from FY2018

| NYSE MARKET INDEX | | $ | 100.00 | | | $ | 106.75 | | | $ | 102.38 | | | $ | 114.61 | | | $ | 136.07 | | | $ | 123.89 | |

Dropped from FY2018

| SIC CODE INDEX | | $ | 100.00 | | | $ | 127.50 | | | $ | 141.59 | | | $ | 130.44 | | | $ | 199.51 | | | $ | 210.24 | |

Dropped from FY2018

| S&P 500 INDEX | | $ | 100.00 | | | $ | 113.69 | | | $ | 115.26 | | | $ | 129.05 | | | $ | 157.22 | | | $ | 150.33 | |

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

| September 30 to October 27, 2018 | | | 128 | | | $ | 182.79 | | | | 128 | | | $ | 2,968,685 | |

Dropped from FY2018

| October 28 to November 24, 2018 | | | 1,126 | | | $ | 195.56 | | | | 1,126 | | | $ | 2,748,484 | |

Dropped from FY2018

| November 25 to December 31, 2018 | | | 1,466 | | | $ | 189.54 | | | | 1,460 | | | $ | 2,471,785 | |

Dropped from FY2018

| Total | | | 2,720 | | | $ | 191.71 | | | | 2,714 | | | $ | 2,471,785 | |

Dropped from FY2018

##### [Table of Contents](#toc)

Item 6. Selected Financial Data

23 rewritten, 8 added, 2 removed, 5 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

The statement of operations and balance sheet data is derived from financial statements for the years [added: 2019,] 2018, 2017, [removed: 2016, 2015] [added: 2016] and [removed: 2014.][added: 2015.]

Rewritten

The Company’s financial statements as of December 31, [removed: 2018] [added: 2019] and [removed: 2017,] [added: 2018,] and for each of the three years in the period ended December 31, [removed: 2018] [added: 2019] are included in Part II, Item 8, Financial Statements and Supplementary Data, of this Form [removed: 10-K.]

Rewritten

| [removed: In] [added: In] thousands, except per [removed: share and] [added: share and] employees [removed: data] [added: data] | | [removed: 2018] [added: 2019] | | | | [removed: 2017] [added: 2018] | | | | [removed: 2016] [added: 2017] | | | | [removed: 2015] [added: 2016] | | | | [removed: 2014] [added: 2015] | | |

Rewritten

| [removed: STATEMENT] [added: STATEMENT] OF OPERATIONS [removed: DATA:] [added: DATA:] | | | | | | | | | | | | | | | | | | | | |

Rewritten

| Net sales | | $ | [removed: 2,419,929] [added: 2,406,596] | | | $ | [removed: 2,309,078] [added: 2,419,929] | | | $ | [removed: 2,167,423] [added: 2,309,078] | | | $ | [removed: 2,042,332] [added: 2,167,423] | | | $ | [removed: 1,989,344] [added: 2,042,332] | |

Rewritten

| Income from operations before income taxes | | $ | [removed: 682,146] [added: 678,239] | | | $ | [removed: 641,097] [added: 682,146] | | | $ | [removed: 600,114] [added: 641,097] | | | $ | [removed: 541,918] [added: 600,114] | | | $ | [removed: 490,740] [added: 541,918] | |

Rewritten

| Net income* | | $ | [removed: 593,794] [added: 592,198] | | | $ | [removed: 20,311] [added: 593,794] | | | $ | [removed: 521,503] [added: 20,311] | | | $ | [removed: 469,275] [added: 521,503] | | | $ | [removed: 431,620] [added: 469,275] | |

Rewritten

| Net income per basic common share* | | $ | [removed: 7.71] [added: 8.76] | | | $ | [removed: 0.25] [added: 7.71] | | | $ | [removed: 6.46] [added: 0.25] | | | $ | [removed: 5.70] [added: 6.46] | | | $ | [removed: 5.12] [added: 5.70] | |

Rewritten

| Weighted-average number of basic common shares | | | [removed: 76,992] [added: 67,627] | | | | [removed: 79,793] [added: 76,992] | | | | [removed: 80,786] [added: 79,793] | | | | [removed: 82,336] [added: 80,786] | | | | [removed: 84,358] [added: 82,336] | |

Rewritten

| Net income per diluted common share* | | $ | [removed: 7.65] [added: 8.69] | | | $ | [removed: 0.25] [added: 7.65] | | | $ | [removed: 6.41] [added: 0.25] | | | $ | [removed: 5.65] [added: 6.41] | | | $ | [removed: 5.07] [added: 5.65] | |

Rewritten

| Weighted-average number of diluted common shares and equivalents | | | [removed: 77,618] [added: 68,166] | | | | [removed: 80,604] [added: 77,618] | | | | [removed: 81,417] [added: 80,604] | | | | [removed: 83,087] [added: 81,417] | | | | [removed: 85,151] [added: 83,087] | |

Rewritten

| [removed: BALANCE] [added: BALANCE] SHEET AND OTHER [removed: DATA:] [added: DATA:] | | | | | | | | | | | | | | | | | | | | |

Rewritten

| Cash, cash equivalents and investments | | $ | [removed: 1,735,224] [added: 337,144] | | | $ | [removed: 3,393,701] [added: 1,735,224] | | | $ | [removed: 2,813,032] [added: 3,393,701] | | | $ | [removed: 2,399,263] [added: 2,813,032] | | | $ | [removed: 2,055,388] [added: 2,399,263] | |

Rewritten

| Working capital, including current maturities of debt | | $ | [removed: 2,214,232] [added: 721,157] | | | $ | [removed: 3,663,977] [added: 2,214,232] | | | $ | [removed: 3,115,124] [added: 3,663,977] | | | $ | [removed: 2,649,457] [added: 3,115,124] | | | $ | [removed: 2,236,558] [added: 2,649,457] | |

Rewritten

| Total assets | | $ | [removed: 3,727,426] [added: 2,557,055] | | | $ | [removed: 5,324,354] [added: 3,727,426] | | | $ | [removed: 4,662,059] [added: 5,324,354] | | | $ | [removed: 4,268,677] [added: 4,662,059] | | | $ | [removed: 3,874,690] [added: 4,268,677] | |

Rewritten

| Long-term [removed: debt] [added: debt] | | $ | [removed: 1,148,172] [added: 1,580,797] | | | $ | [removed: 1,897,501] [added: 1,148,172] | | | $ | [removed: 1,701,966] [added: 1,897,501] | | | $ | [removed: 1,493,027] [added: 1,701,966] | | | $ | [removed: 1,237,463] [added: 1,493,027] | |

Rewritten

| Stockholders’ [added: (deficit)] equity* | | $ | [removed: 1,567,258] [added: (216,281] | [added: )] | | $ | [removed: 2,233,788] [added: 1,567,258] | | | $ | [removed: 2,301,949] [added: 2,233,788] | | | $ | [removed: 2,058,851] [added: 2,301,949] | | | $ | [removed: 1,894,666] [added: 2,058,851] | |

Rewritten

| Employees | | | [removed: 7,246] [added: 7,467] | | | | [removed: 7,020] [added: 7,246] | | | | [removed: 6,899] [added: 7,020] | | | | [removed: 6,594] [added: 6,899] | | | | [removed: 6,161] [added: 6,594] | |

Rewritten

This aspect of the new accounting guidance was required to be adopted on a prospective basis for the statement of operations and retroactive restatement [removed: is] [added: was] not permitted.

Rewritten

In [added: 2019,] 2018 and 2017, the Company recognized an excess tax benefit, which decreased income tax expense by $9 [added: million, $9] million and $20 million, respectively, and added [added: $0.14,] $0.11 and $0.24, respectively, to net income per diluted share.

Rewritten

[removed: In addition, in December 2018, the Company settled a pension plan obligation by making lump-sum] cash payments and purchasing annuity contracts for participants to permanently extinguish the pension plan’s obligations.

Rewritten

As a result, the Company recorded a $46 million charge, which consisted of a $6 million cash contribution to the plan and a $40 million [removed: non-cash charge related to the reversal of unrecognized actuarial losses recorded in accumulated other comprehensive income in the stockholders’ equity.]

Rewritten

[removed: The $46 million pre-tax] charge reduced net income per diluted share by $0.39.

New in FY2019

10-K.

New in FY2019

In addition, in December 2018, the Company settled a pension plan obligation by making

New in FY2019

lump-sum

New in FY2019

non-cash

New in FY2019

charge related to the reversal of unrecognized actuarial losses recorded in accumulated other comprehensive income in the stockholders’ equity.

New in FY2019

The $46 million

New in FY2019

pre-tax

New in FY2019

| | In January 2019, the company adopted new accounting guidance related to the accounting for leases. The new guidance requires lessees to present the assets and liabilities that arise from leases on their balance sheets. The standard required using a modified retrospective transition approach to be applied to leases existing as of, or entered into after, January 1, 2019. As a result, the Company recorded a $93 million right-of-use asset as of December 31, 2019. The adoption of this standard did not have a material impact on the Company’s results of operations, cash flows and stockholder’s (deficit) equity. |

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

| | In 2015, the Company adopted new accounting guidance related to the presentation of debt issuance costs and deferred income taxes, both standards have been applied above retrospectively. Certain debt issuance costs have been reclassified from intangible assets and are presented as a direct deduction from the carrying value of the associated debt. Current deferred tax assets and liabilities have been reclassified as non-current deferred tax assets and liabilities. |

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

0 rewritten, 1 added, 0 removed, 1 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

New in FY2019

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure

Item 9A. Controls and Procedures

9 rewritten, 14 added, 0 removed, 0 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

[removed: _Evaluation] [added: Evaluation] of Disclosure Controls and [removed: Procedures_][added: Procedures]

Rewritten

The Company’s chief executive officer and chief financial officer (principal executive officer and principal financial officer), with the participation of management, evaluated the effectiveness of the Company’s disclosure controls and procedures (as defined in Rules [removed: 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this annual report on Form 10-K.]

Rewritten

Based on this evaluation, the Company’s chief executive officer and chief financial officer concluded that the Company’s disclosure controls and procedures were effective as of December 31, [removed: 2018] [added: 2019] (1) to ensure that information required to be disclosed by the Company, including its consolidated subsidiaries, in the reports that it files or submits under the Exchange Act is accumulated and communicated to the Company’s management, including its chief executive officer and chief financial officer, to allow timely decisions regarding the required disclosure and (2) to provide reasonable assurance that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms.

Rewritten

[removed: _Management’s] [added: Management’s] Annual Report on Internal Control Over Financial [removed: Reporting_][added: Reporting]

Rewritten

See Management’s Report on Internal Control Over Financial Reporting in Item 8 on page [removed: 49] [added: 46] of this Form [removed: 10-K.]

Rewritten

[removed: _Report] [added: Report] of the Independent Registered Public Accounting [removed: Firm_][added: Firm]

Rewritten

See the report of PricewaterhouseCoopers LLP in Item 8 [added: beginning] on page [removed: 50] [added: 47] of this Form [removed: 10-K.]

Rewritten

[removed: _Changes] [added: Changes] in Internal [removed: Controls] [added: Control] Over Financial [removed: Reporting_][added: Reporting]

Rewritten

[removed: No change was identified in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f)] under the Exchange Act) during the quarter ended December 31, [removed: 2018] [added: 2019] that has materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.

New in FY2019

13a-15(e)

New in FY2019

and

New in FY2019

15d-15(e)

New in FY2019

under the Exchange Act) as of the end of the period covered by this annual report on Form

New in FY2019

10-K.

New in FY2019

10-K.

New in FY2019

10-K.

New in FY2019

No change was identified in the Company’s internal control over financial reporting (as defined in Rules

New in FY2019

13a-15(f)

New in FY2019

and

New in FY2019

15d-15(f)

New in FY2019

| Item 9B: Other | Information |

New in FY2019

None.

New in FY2019

PART III

Item 10. Directors, Executive Officers and Corporate Governance

7 rewritten, 6 added, 2 removed, 7 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

Information regarding the Company’s directors and any material changes to the process by which security holders may recommend nominees to the Board of Directors is contained in the definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the headings “Election of Directors”, “Directors Meetings and Board Committees”, “Corporate Governance”, “Report of the Audit Committee of the Board of Directors” and “Compensation of Directors and Executive Officers”.

Rewritten

Information regarding compliance with Section 16(a) of the Exchange Act is contained in the Company’s definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the heading [removed: “Section] [added: “Delinquent Section] 16(a) [removed: Beneficial Ownership Reporting Compliance”.][added: Reports”.]

Rewritten

Information regarding the Company’s Audit Committee and Audit Committee Financial Expert is contained in the definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the headings “Report of the Audit Committee of the Board of Directors” and “Directors Meetings and Board Committees”.

Rewritten

Information regarding the Company’s executive officers is contained in Part I of this Form [removed: 10-K.]

Rewritten

The Company has adopted a Global Code of Business Conduct & Ethics (the “Code”) that applies to all of the Company’s employees (including its executive officers) and directors and that is in compliance with Item 406 of Regulation [removed: S-K.]

Rewritten

In addition, the Code is available on the Company’s website, [removed: www.waters.com, under the caption “Corporate Governance”.]

Rewritten

The Company’s corporate governance guidelines and the charters of the audit committee, compensation committee, finance committee and nominating and corporate governance committee of the Board of Directors are available on the Company’s website, [removed: www.waters.com, under the caption “Corporate Governance”.]

New in FY2019

10-K.

New in FY2019

S-K.

New in FY2019

www.waters.com

New in FY2019

, under the caption “Corporate Governance”.

New in FY2019

www.waters.com

New in FY2019

, under the caption “Corporate Governance”.

Dropped from FY2018

In 2017, the Company adopted a proxy access bylaw provision that allows eligible stockholders or groups of up to 20 stockholders who have held at least 3% of the Company’s common stock continuously for three years to nominate up to two individuals or 20% of the Board of Directors, whichever is greater, for election at the Company’s Annual Meeting of Stockholders, and to have those individuals included in the Company’s proxy materials for that meeting.

Dropped from FY2018

The Company believes that the proxy access bylaw adopted by the Company strikes an appropriate balance between providing meaningful proxy access for stockholders and limiting the potential for abuse.

Item 11. Executive Compensation

1 rewritten, 0 added, 0 removed, 1 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

This information is contained in the Company’s definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the headings “Compensation of Directors and Executive Officers”, “Compensation Committee Interlocks and Insider Participation” and “Compensation Committee Report”.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

7 rewritten, 9 added, 3 removed, 2 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

Except for the Equity Compensation Plan information set forth below, this information is contained in the Company’s definitive proxy statement for the [removed: 2019] [added: 2020] Annual Meeting of Stockholders under the heading “Security Ownership of Certain Beneficial Owners and Management”.

Rewritten

[removed: Equity] [added: Equity] Compensation Plan [removed: Information][added: Information]

Rewritten

The following table provides information as of December 31, [removed: 2018] [added: 2019] about the Company’s common stock that may be issued upon the exercise of options, [removed: warrants,] [added: warrants] and rights under its existing equity compensation plans (in thousands):

Rewritten

| | | [removed: Number] [added: Number] of Securities to be Issued Upon Exercise of Outstanding Options, Warrants and Rights [removed: (1)] [added: (1)] | | | | [removed: Weighted-Average] [added: Weighted-Average] Exercise Price of Outstanding Options, Warrants and Rights [removed: (1)] [added: (1)] | | | | [removed: Number] [added: Number] of Securities Remaining Available for Future Issuance Under Equity Compensation Plans (excluding securities reflected in column [removed: (A))] [added: (A))] | | |

Rewritten

| Equity compensation plans approved by security holders | | | [removed: 2,234] [added: 1,861] | | | $ | [removed: 142.47] [added: 158.61] | | | | [removed: 3,005] [added: 2,711] | |

Rewritten

| (1) | Column (a) includes an aggregate of [removed: 444] [added: 406] shares of common stock to be issued upon settlement of restricted stock, restricted stock units and performance stock units. The weighted-average share price in column (b) does not take into account restricted stock, restricted stock units or performance stock units, which do not have an exercise price. |

Rewritten

See Note [removed: 13,] [added: 14,] Stock-Based Compensation, in the Notes to Consolidated Financial Statements for a description of the material features of the Company’s equity compensation plans.

New in FY2019

| | | A | | | | B | | | | C | | |

New in FY2019

| Total | | | 1,861 | | | $ | 158.61 | | | | 2,711 | |

New in FY2019

| Item | 13: Certain Relationships and Related Transactions and Director Independence |

New in FY2019

This information is contained in the Company’s definitive proxy statement for the 2020 Annual Meeting of Stockholders under the headings “Directors Meetings and Board Committees”, “Corporate Governance” and “Compensation of Directors and Executive Officers”.

New in FY2019

Such information is incorporated herein by reference.

New in FY2019

| Item | 14: Principal Accountant Fees and Services |

New in FY2019

This information is contained in the Company’s definitive proxy statement for the 2020 Annual Meeting of Stockholders under the headings “Ratification of Selection of Independent Registered Public Accounting Firm” and “Report of the Audit Committee of the Board of Directors”.

New in FY2019

Such information is incorporated herein by reference.

New in FY2019

PART IV

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

| | | A | | | | B | | | | C | | |

Dropped from FY2018

| Total | | | 2,234 | | | $ | 142.47 | | | | 3,005 | |

Item 15. Exhibits, Financial Statement Schedules

61 rewritten, 42 added, 17 removed, 36 unchanged

Read the full itemFY2019 item · filed February 25, 2020FY2018 item · filed February 26, 2019

Rewritten

The consolidated financial statements of the Company and its subsidiaries are filed as part of this Form [removed: 10-K and are set forth on pages 52 to 97.]

Rewritten

The report of PricewaterhouseCoopers LLP, an independent registered public accounting firm, dated February [removed: 26, 2019,] [added: 25, 2020,] is set forth [added: beginning] on page [removed: 50] [added: 47] of this Form [removed: 10-K.]

Rewritten

[removed: | | (2) |] [added: Exhibits,] Financial Statement [removed: Schedule: |][added: Schedules]

Rewritten

| | [removed: (3)] [added: (2)] | Exhibits: |

Rewritten

| [removed: Exhibit Number] [added: Exhibit Number] | | [removed: Description] [added: | | Description] of [removed: Document] [added: Document] |

Rewritten

| [added: |] 3.1 | | [added: |] Second Amended and Restated Certificate of Incorporation of Waters Corporation.(1)(P) |

Rewritten

| [added: |] 3.2 | | [added: |] [Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Waters Corporation, dated as of May 12, 1999.(3)](http://www.sec.gov/Archives/edgar/data/1000697/000104746999030964/0001047469-99-030964.txt) |

Rewritten

| [added: |] 3.3 | | [added: |] [Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Waters Corporation, dated as of July 27, 2000.(4)](http://www.sec.gov/Archives/edgar/data/1000697/000091205700035253/ex-3_12.txt) |

Rewritten

| [added: |] 3.4 | | [added: |] [Certificate of Amendment of Second Amended and Restated Certificate of Incorporation of Waters Corporation, dated as of May 25, 2001.(5)](http://www.sec.gov/Archives/edgar/data/1000697/000092701602001727/dex313.txt) |

Rewritten

| [added: |] 3.5 | | [added: |] [Amended and Restated Bylaws of Waters Corporation, dated as of December 5, 2017.(29)](http://www.sec.gov/Archives/edgar/data/1000697/000119312517364940/d470585dex31.htm) |

Rewritten

| [added: |] 10.1 | | [added: |] Waters Corporation Retirement Plan.(2)(P)(*) |

Rewritten

| [added: |] 10.2 | | [added: |] [Waters Corporation 2003 Equity Incentive Plan.(6)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013503005751/b48537wcexv4w1.txt) |

Rewritten

| [added: |] 10.3 | | [added: |] [First Amendment to the Waters Corporation 2003 Equity Incentive Plan.(7)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504001254/b48994wcexv10w17.txt) |

Rewritten

| [added: |] 10.4 | | [added: |] [Form of Director Stock Option Agreement under the Waters Corporation 2003 Equity Incentive Plan, as amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w27.txt) |

Rewritten

| [added: |] 10.5 | | [added: |] [Form of Director Restricted Stock Agreement under the Waters Corporation 2003 Equity Incentive Plan, as amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w28.txt) |

Rewritten

| [added: |] 10.6 | | [added: |] [Form of Executive Officer Stock Option Agreement under the Waters Corporation 2003 Equity Incentive Plan, as amended.(8)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013504005261/b52084wcexv10w29.txt) |

Rewritten

| [added: |] 10.7 | | [added: |] [Second Amendment to the Waters Corporation 2003 Equity Incentive Plan.(9)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013505004504/b55598wcexv10w38.htm) |

Rewritten

| [added: |] 10.8 | | [added: |] [Third Amendment to the Waters Corporation 2003 Equity Incentive Plan.(10)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507001300/b63656wcexv10w48.txt) |

Rewritten

| [added: |] 10.9 | | [added: |] [Amended and Restated Waters 401(k) Restoration Plan, effective January 1, 2008.(11)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013507006667/b67183wcexv10w52.htm) |

Rewritten

| [added: |] 10.10 | | [added: |] [Change of Control/Severance Agreement, dated as of February 27, 2008, between Waters Corporation and Mark T. Beaudouin.(12)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013508001339/b68112wcexv10w53.htm) |

Rewritten

| [added: |] 10.11 | | [added: |] [Change of Control/Severance Agreement, dated as of February 27, 2008, between Waters Corporation and Elizabeth B. Rae.(12)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013508001339/b68112wcexv10w58.htm) |

Rewritten

| [added: |] 10.12 | | [added: |] [Change of Control/Severance Agreement, dated as of February 27, 2008, between Waters Corporation and Eugene G. Cassis.(21)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515067900/d849246dex1014.htm) |

Rewritten

| [removed: Exhibit Number] [added: Exhibit Number] | | [removed: Description] [added: | | Description] of [removed: Document] [added: Document] |

Rewritten

| [added: |] 10.13 | | [added: |] [Amended and Restated Waters Retirement Restoration Plan, effective January 1, 2008.(13)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013509001331/b72903wcexv10w49.htm) |

Rewritten

| [added: |] 10.14 | | [added: |] [Amended and Restated Waters Corporation 1996 Non-Employee Director Deferred Compensation Plan, Effective January 1, 2008.(13)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095013509001331/b72903wcexv10w5.htm) |

Rewritten

| [added: |] 10.15 | | [added: |] [2014 Waters Corporation Management Incentive Plan.(21)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515067900/d849246dex1017.htm) |

Rewritten

| [added: |] 10.16 | | [added: |] [Waters Corporation 2009 Employee Stock Purchase Plan.(14)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000095012309021422/b76149wcexv4w1.htm) |

Rewritten

| [added: |] 10.17 | | [added: |] [Note Purchase Agreement, dated as of February 1, 2010, between Waters Corporation and the purchases named therein.(15)](http://www.sec.gov/Archives/edgar/data/1000697/000095012310017583/b78684exv10w61.htm) |

Rewritten

| [added: |] 10.18 | | [added: |] [First Amendment to the Note Purchase Agreement, dated as of February 1, 2010.(16)](http://www.sec.gov/Archives/edgar/data/1000697/000095012311046109/b85480exv10w63.htm) |

Rewritten

| [added: |] 10.19 | | [added: |] [Note Purchase Agreement, dated March 15, 2011, between Waters Corporation and the purchases named therein.(16)](http://www.sec.gov/Archives/edgar/data/1000697/000095012311046109/b85480exv10w62.htm) |

Rewritten

| [added: |] 10.20 | | [added: |] [Waters Corporation 2012 Equity Incentive Plan.(17)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512380231/d404655dex41.htm) |

Rewritten

| [added: |] 10.21 | | [added: |] [Form of Waters 2012 Stock Option Agreement - Executive Officers.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex101.htm) |

Rewritten

| [added: |] 10.22 | | [added: |] [Form of Waters 2012 Stock Option Agreement - Directors.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex102.htm) |

Rewritten

| [added: |] 10.23 | | [added: |] [Form of Waters 2012 Restricted Stock Agreement - Directors.(18)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312512498191/d453660dex103.htm) |

Rewritten

| [added: |] 10.24 | | [added: |] [Form of Waters 2012 Restricted Stock Unit Agreement for Executive Officers - Five Year Vesting.(19)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312513469540/d644445dex101.htm) |

Rewritten

| [added: |] 10.25 | | [added: |] [Form of Waters 2012 Restricted Stock Unit Agreement for Executive Officers - One Year Vesting.(19)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312513469540/d644445dex102.htm) |

Rewritten

| [added: |] 10.26 | | [added: |] [Note Purchase Agreement, dated June 30, 2014, between Waters Corporation and the purchases named therein.(20)](http://www.sec.gov/Archives/edgar/data/1000697/000119312514290679/d760078dex101.htm) |

Rewritten

| [added: |] 10.27 | | [added: |] [Change of Control/Severance Agreement, dated as of April 1, 2015, between Waters Corporation and Michael F. Silveira.(22)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515178581/d919579dex101.htm) |

Rewritten

| [added: |] 10.28 | | [added: |] [President and Chief Executive Employment Agreement.(23)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515282127/d84496dex101.htm) |

Rewritten

| [added: |] 10.29 | | [added: |] [Change of Control/Severance Agreement, dated as of September 8, 2015, between Waters Corporation and Christopher J. O’Connell.(23)(*)](http://www.sec.gov/Archives/edgar/data/1000697/000119312515282127/d84496dex102.htm) |

New in FY2019

10-K

New in FY2019

and are set forth on pages 50 to 95.

New in FY2019

10-K.

New in FY2019

| | 4.1 | | | [Description of Registrant’s Securities](https://www.sec.gov/Archives/edgar/data/1000697/000119312520048303/d862312dex41.htm) |

New in FY2019

| | 10.42 | | | [Note Purchase Agreement, dated as of September 12, 2019, between Waters Corporation and the purchasers named therein.(32)](http://www.sec.gov/Archives/edgar/data/1000697/000119312519245825/d804960dex101.htm) |

New in FY2019

| | 10.43 | | | [Form of Performance Stock Unit Award Agreement under the Waters Corporation 2012 Equity Incentive Plan(*)](https://www.sec.gov/Archives/edgar/data/1000697/000119312520048303/d862312dex1043.htm) |

New in FY2019

| | 104 | | | Cover Page Interactive Date File (formatted in iXBRL and contained in Exhibit 101). |

New in FY2019

| (31) | Incorporated by reference to the Registrant’s Report on Form 10-K/A dated March 1, 2019 (File No. 001-14010). |

New in FY2019

| (32) | Incorporated by reference to the Registrant’s Report on Form 8-K dated September 16, 2019 (File No. 001-14010). |

New in FY2019

| Item | 16: Form 10-K Summary |

New in FY2019

The optional summary in Item 16 has not been included in this Form

New in FY2019

10-K.

New in FY2019

SIGNATURES

New in FY2019

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

New in FY2019

| /s/ Sherry L. Buck |

New in FY2019

| Sherry L. Buck |

New in FY2019

| Senior Vice President and |

New in FY2019

| Chief Financial Officer |

New in FY2019

Date: February 25, 2020

New in FY2019

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated on February 25, 2020.

New in FY2019

| /s/ Christopher J. O’Connell | | Chairman of the Board of Directors and Chief |

New in FY2019

| Christopher J. O’Connell | | Executive Officer (principal executive officer) |

New in FY2019

| /s/ Sherry L. Buck | | Senior Vice President and Chief Financial Officer |

New in FY2019

| Sherry L. Buck | | (principal financial officer) (principal accounting officer) |

New in FY2019

| /s/ Linda Baddour | | Director |

New in FY2019

| Linda Baddour | | |

New in FY2019

| /s/ Dr. Michael J. Berendt | | Director |

New in FY2019

| Dr. Michael J. Berendt | | |

New in FY2019

| /s/ Edward Conard | | Director |

New in FY2019

| Edward Conard | | |

New in FY2019

| /s/ Dr. Laurie H. Glimcher | | Director |

New in FY2019

| Dr. Laurie H. Glimcher | | |

New in FY2019

| /s/ Gary Hendrickson | | Director |

New in FY2019

| Gary Hendrickson | | |

New in FY2019

| /s/ Christopher A. Kuebler | | Director |

New in FY2019

| Christopher A. Kuebler | | |

New in FY2019

| /s/ Flemming Ornskov | | Director |

New in FY2019

| Flemming Ornskov | | |

New in FY2019

| /s/ JoAnn A. Reed | | Director |

New in FY2019

| JoAnn A. Reed | | |

Dropped from FY2018

See (c) below.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

| (c) | Financial Statement Schedule: |

Dropped from FY2018

The following additional financial statement schedule should be considered in conjunction with the consolidated financial statements.

Dropped from FY2018

All other schedules have been omitted because the required information is either not applicable or not sufficiently material to require submission of the schedule.

Dropped from FY2018

SCHEDULE II - VALUATION AND QUALIFYING ACCOUNTS

Dropped from FY2018

For each of the three years in the period ended December 31, 2018

Dropped from FY2018

| | | Balance at Beginning of Period | | | | Charged to Provision for Income Taxes* | | | | Other | | | | Balance at End of Period | | |

Dropped from FY2018

| Valuation allowance for deferred tax assets: | | | | | | | | | | | | | | | | |

Dropped from FY2018

| 2018 | | $ | 62,098 | | | $ | (2,128 | ) | | $ | (6,077 | ) | | $ | 53,893 | |

Dropped from FY2018

| 2017 | | $ | 61,225 | | | $ | (6,363 | ) | | $ | 7,236 | | | $ | 62,098 | |

Dropped from FY2018

| 2016 | | $ | 68,595 | | | $ | (5,473 | ) | | $ | (1,897 | ) | | $ | 61,225 | |

Dropped from FY2018

| * | These amounts have been recorded as part of the income statement provision for income taxes. The income statement effects of these amounts have largely been offset by amounts related to changes in other deferred tax balance sheet accounts. |

Dropped from FY2018

| | The change in the valuation allowance during the year ended December 31, 2018 is primarily due to the write-off of a valuation allowance to Retained Earnings for the tax effect related to intra-entity asset transfers. The change in the valuation allowance during the years ended December 31, 2017 and 2016 is primarily due to the effect of foreign currency translation on a valuation allowance related to a net operating loss carryforward. In addition, 2016 includes the release of a valuation allowance related to a foreign tax credit carryforward due to expiration. |

An excerpt. Shown here: 40 of 61 rewritten, 40 of 42 added and all 17 removed. The counts are complete. For every sentence, read Item 15. Exhibits, Financial Statement Schedules in the FY2019 filing and the FY2018 filing.

Item 1B. Unresolved Staff Comments

0 rewritten, 0 added, 2 removed, 0 unchanged

Dropped this year

Read the full itemFY2018 item · filed February 26, 2019

Dropped from FY2018

None.

Dropped from FY2018

##### [Table of Contents](#toc)

Item 8. Financial Statements and Supplementary Data

0 rewritten, 0 added, 1,418 removed, 0 unchanged

Dropped this year

Read the full itemFY2018 item · filed February 26, 2019

Dropped from FY2018

Management’s Report on Internal Control Over Financial Reporting

Dropped from FY2018

Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act.

Dropped from FY2018

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Dropped from FY2018

Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Dropped from FY2018

Under the supervision and with the participation of our management, including our chief executive officer and chief financial officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in _Internal Control_ _— Integrated Framework (2013)_ issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Dropped from FY2018

Based on our evaluation under the framework in _Internal Control_ _— Integrated Framework (2013)_, our management, including our chief executive officer and chief financial officer, concluded that our internal control over financial reporting was effective as of December 31, 2018.

Dropped from FY2018

The effectiveness of our internal control over financial reporting as of December 31, 2018 has been audited by PricewaterhouseCoopers LLP, an independent registered public accounting firm, as stated in their report which is included herein.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

Report of Independent Registered Public Accounting Firm

Dropped from FY2018

To the Board of Directors and Stockholders of Waters Corporation

Dropped from FY2018

_Opinions on the Financial Statements and Internal Control over Financial Reporting_

Dropped from FY2018

We have audited the accompanying consolidated balance sheets of Waters Corporation and its subsidiaries (the “Company”) as of December 31, 2018 and 2017, and the related consolidated statements of operations, comprehensive income, stockholders’ equity and cash flows for each of the three years in the period ended December 31, 2018, including the related notes and schedule of valuation and qualifying accounts for each of the three years in the period ended December 31, 2018 appearing under Item 15(c) (collectively referred to as the “consolidated financial statements”).

Dropped from FY2018

We also have audited the Company’s internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control — Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO).

Dropped from FY2018

In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the financial position of the Company as of December 31, 2018 and 2017, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2018 in conformity with accounting principles generally accepted in the United States of America.

Dropped from FY2018

Also in our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2018, based on criteria established in Internal Control — Integrated Framework (2013) issued by the COSO.

Dropped from FY2018

_Change in Accounting Principle_

Dropped from FY2018

As discussed in Note 10 to the consolidated financial statements, the Company changed the manner in which it accounts for share-based payment transactions in 2017.

Dropped from FY2018

_Basis for Opinions_

Dropped from FY2018

The Company’s management is responsible for these consolidated financial statements, for maintaining effective internal control over financial reporting, and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management’s Report on Internal Control Over Financial Reporting.

Dropped from FY2018

Our responsibility is to express opinions on the Company’s consolidated financial statements and on the Company’s internal control over financial reporting based on our audits.

Dropped from FY2018

We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

Dropped from FY2018

We conducted our audits in accordance with the standards of the PCAOB.

Dropped from FY2018

Those standards require that we plan and perform the audits to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud, and whether effective internal control over financial reporting was maintained in all material respects.

Dropped from FY2018

Our audits of the consolidated financial statements included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks.

Dropped from FY2018

Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements.

Dropped from FY2018

Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements.

Dropped from FY2018

Our audit of internal control over financial reporting included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk.

Dropped from FY2018

Our audits also included performing such other procedures as we considered necessary in the circumstances.

Dropped from FY2018

We believe that our audits provide a reasonable basis for our opinions.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

_Definition and Limitations of Internal Control over Financial Reporting_

Dropped from FY2018

A company’s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles.

Dropped from FY2018

A company’s internal control over financial reporting includes those policies and procedures that (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company’s assets that could have a material effect on the financial statements.

Dropped from FY2018

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements.

Dropped from FY2018

Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Dropped from FY2018

| /s/ PricewaterhouseCoopers LLP |

Dropped from FY2018

| Boston, Massachusetts |

Dropped from FY2018

| February 26, 2019 |

Dropped from FY2018

We have served as the Company’s auditor since 1994.

Dropped from FY2018

##### [Table of Contents](#toc)

An excerpt. Shown here: all 0 rewritten, all 0 added and 40 of 1,418 removed. The counts are complete. For every sentence, read Item 8. Financial Statements and Supplementary Data in the FY2018 filing.

Item 9B. Other Information

0 rewritten, 0 added, 3 removed, 0 unchanged

Dropped this year

Read the full itemFY2018 item · filed February 26, 2019

Dropped from FY2018

None.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

PART III

Item 13. Certain Relationships and Related Transactions and Director Independence

0 rewritten, 0 added, 2 removed, 0 unchanged

Dropped this year

Read the full itemFY2018 item · filed February 26, 2019

Dropped from FY2018

This information is contained in the Company’s definitive proxy statement for the 2019 Annual Meeting of Stockholders under the headings “Directors Meetings and Board Committees”, “Corporate Governance” and “Compensation of Directors and Executive Officers”.

Dropped from FY2018

Such information is incorporated herein by reference.

Item 14. Principal Accountant Fees and Services

0 rewritten, 0 added, 4 removed, 0 unchanged

Dropped this year

Read the full itemFY2018 item · filed February 26, 2019

Dropped from FY2018

This information is contained in the Company’s definitive proxy statement for the 2019 Annual Meeting of Stockholders under the headings “Ratification of Selection of Independent Registered Public Accounting Firm” and “Report of the Audit Committee of the Board of Directors”.

Dropped from FY2018

Such information is incorporated herein by reference.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

PART IV

Item 16. Form 10-K Summary

0 rewritten, 0 added, 33 removed, 0 unchanged

Dropped this year

Read the full itemFY2018 item · filed February 26, 2019

Dropped from FY2018

The optional summary in Item 16 has not been included in this Form 10-K.

Dropped from FY2018

##### [Table of Contents](#toc)

Dropped from FY2018

SIGNATURES

Dropped from FY2018

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dropped from FY2018

| WATERS CORPORATION |

Dropped from FY2018

| /s/ SHERRY L. BUCK |

Dropped from FY2018

| Sherry L. Buck |

Dropped from FY2018

| _Senior Vice President and_ |

Dropped from FY2018

| _Chief Financial Officer_ |

Dropped from FY2018

Date: February 26, 2019

Dropped from FY2018

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed by the following persons on behalf of the registrant and in the capacities indicated on February 26, 2019.

Dropped from FY2018

| /S/ CHRISTOPHER J. O’CONNELL | | Chairman of the Board of Directors and Chief |

Dropped from FY2018

| Christopher J. O’Connell | | Executive Officer (principal executive officer) |

Dropped from FY2018

| /S/ SHERRY L. BUCK | | Senior Vice President and Chief Financial Officer |

Dropped from FY2018

| Sherry L. Buck | | (principal financial officer) (principal accounting officer) |

Dropped from FY2018

| /S/ LINDA BADDOUR | | Director |

Dropped from FY2018

| Linda Baddour | | |

Dropped from FY2018

| /S/ DR. MICHAEL J. BERENDT | | Director |

Dropped from FY2018

| Dr. Michael J. Berendt | | |

Dropped from FY2018

| /S/ EDWARD CONARD | | Director |

Dropped from FY2018

| Edward Conard | | |

Dropped from FY2018

| /S/ DR. LAURIE H. GLIMCHER | | Director |

Dropped from FY2018

| Dr. Laurie H. Glimcher | | |

Dropped from FY2018

| /S/ GARY HENDRICKSON | | Director |

Dropped from FY2018

| Gary Hendrickson | | |

Dropped from FY2018

| /S/ CHRISTOPHER A. KUEBLER | | Director |

Dropped from FY2018

| Christopher A. Kuebler | | |

Dropped from FY2018

| /S/ FLEMMING ORNSKOV | | Director |

Dropped from FY2018

| Flemming Ornskov | | |

Dropped from FY2018

| /S/ JOANN A. REED | | Director |

Dropped from FY2018

| JoAnn A. Reed | | |

Dropped from FY2018

| /S/ THOMAS P. SALICE | | Director |

Dropped from FY2018

| Thomas P. Salice | | |